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General Introduction
1. Colorectal Cancer
1.1 Epidemiology
Colorectal Cancer (CRC) constitutes the third cancer type in terms of incidence worldwide, 
with more than 1.3 million new cases diagnosed in 2012 1, which means that 2 new CRC 
cases are diagnosed every minute in the world. In terms of mortality, around 690.000 CRC-
related deaths were reported in the same year, positioning CRC as the fourth cancer type, 
after lung, liver and stomach cancers 1 (Figure 1). Globally, CRC accounts for almost 9,7% 
of the total number of diagnosed cancers worldwide, and for 8,5% of deaths caused by 
cancer 1. 
By sex, CRC represents the third most commonly diagnosed cancer in males after lung 
and prostate cancer, respectively, and it is the fourth cancer-related death cause, after 
lung, liver and stomach cancers. Regarding females, breast cancer leads the list of the 
most diagnosed cancer types, with CRC in the second place, accounting for more than 
610.000 new estimated cases in 2012. After breast and lung cancers, CRC is the third most 
frequent cancer-related death cause in women 2  (Figure 1). 
CRC incidence rates have notably increased in several areas historically at low risk, 
especially including countries in Eastern Asia and Europe 3,4. These unfavorable trends are 
thought to reflect a combination of factors including changes in dietary patterns, obesity and 
an increased prevalence of smoking 3,5,6. While CRC death rates have been decreasing in 
several Western countries, largely resulting from improved treatment and early detection, 
rates continue to increase in many developing countries, with more limited resources and 
health infrastructure, particularly in Central and South America and Eastern Europe 2. 
Figure 1: Estimated new cancer cases and deaths worldwide for leading cancer sites by sex. 
Source: GLOBOCAN 2012.        
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Spain is considered one of the developed countries where CRC incidence rates have 
continued to rise during the last years, especially among men. 24,2 and 43,9 of every 
100.000 women and men were, respectively, diagnosed of CRC in 2012 in Spain 1. In the 
same year, mortality rates were 8,4 and 17,1 (of each 100.000 individuals) for women and 
men, respectively 1. This places CRC as the most diagnosed cancer in Spain (taking both 
sexes into account), and the second in terms of mortality, only after lung cancer 1 (Figure 
2). However, CRC mortality trends in Spain have been decreasing for men since 2001, with 
a mean of 0,5% per year. For women, a decrease of 1,2% per year is registered since the 
mid-90s 6. Galicia is ranked the third Spanish region in terms of CRC mortality, only after 
Asturias and País Vasco, for both sexes, with death rates falling in the same ranges as 
Spanish ones 6.
Recent results from the EUROCARE-5 study, revealed that the European mean age-
standardized 5-year survival for CRC patients was 57,0% in the period 2000-2007 (64,3% 
for the U.S, 2001-2007 7) with negligible differences between sexes. Central and Northern 
European countries displayed slightly higher survival rates, with Southern countries, 
including Spain, presenting rates similar to the European mean (57,1% for Spain) 8. 
European CRC 5-year survival rates were continuously increasing in the last years, with 
30,3% in 1991, and 44,7% in 2002 9.
It is important to mention that CRC survival rates greatly vary depending on the stage on 
which the cancer is detected. When CRC is detected at a localized stage, the 5-year relative 
survival rate is 90,1%. After the cancer regionally spreads to involve adjacent organs or 
lymph nodes, survival rate drops to 69,2%. When the disease has spread to distant organs, 
5-year survival rate is 11,7% (data from 2008, U.S) 7. 
Figure 2: Estimated new cancer cases and deaths in Spain for leading cancer sites. 
Source: GLOBOCAN 2012 
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1.2 Risk factors and causes
1.2.1 Sporadic CRC
Most cases of CRC arise sporadically, and factors like age, previous colonic polyps or 
environmental factors, contribute to the development of CRC 10. About 20% of all patients 
with CRC are supposed to have some component of familial risk, without strictly fulfilling 
criteria for hereditary CRC 10,11. A detailed list of the main risk factors for sporadic CRC is 
shown in Table 1, upper section. 
1.2.2 Hereditary CRC
Between 5-10% of CRC patients develop in the setting of defined hereditary cancer 
syndromes, with Hereditary Nonpolyposis Colorectal Cancer (HNPCC) and Familial 
Adenomatous Polyposis (FAP), as the two main forms of hereditary CRC 10,11. An extended 
list of hereditary CRC syndromes is shown in Table 1, lower section.
1.2.2.1 Familial Adenomatous Polyposis (FAP)
FAP is an autosomal dominant disease caused, in 80% of affected individuals, by a germline 
mutation in the adenomatous polyposis coli (APC) gene 12. Its prevalence is approximately 
1:10.000 births. FAP patients can develop more than 100 colorectal adenomas (50% of 
patients by age 15 years, 95% by age 35 years), and it arises in almost 100% of patients 
by the age of 40 years if left untreated 11. Disease severity is associated with proximity of 
mutations to the central region of APC gene, with mutations between codons 1445 and 
1578 linked to an increased risk of desmoid tumors. A FAP variant is attenuated FAP, with 
patients developing from 10 to 100 adenomas. APC mutations in patients with attenuated 
FAP, are typically located at the 5’ or 3’ ends of the gene 12.
1.2.2.2 Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
HNPCC, also known as Lynch syndrome, is the most common hereditary disorder 
associated with CRC. It displays an autosomal dominant inheritance pattern. The onset 
of the disease is at 45 years on average (versus 63 years for the general population) 10. 
Lynch syndrome is associated with germline mutations in mismatch repair genes (most 
commonly MLH1, MSH2, or MSH6) 12,13. Pathology of CRC on HNPCC affected individuals 
is often poorly differentiated, with an excess of mucoid and signet cell features, a Crohn’s-
like reaction, and an excess of infiltrating lymphocytes within the tumor 10.
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Table 1. CRC Risk factors and causes
Sporadic CRC (88-94%)
Older age
Male sex
Cholecystectomy
Ureterocolic anastomosis
Hormonal factors: nulliparity, late age at first pregnancy, early menopause
Environmental factors
Diet rich in meat and fat, and poor in fiber, folate and calcium
Sedentary lifestyle
Obesity
Diabetes mellitus
Smoking
Previous irradiation
Occupational hazards (e.g. asbestos exposure)
High alcohol intake
Personal history of sporadic tumors
History of colorectal polyps
History of colorectal cancer
History of small bowel, endometrial, breast, or ovarian cancer
Familial CRC (20%)
First or second degree relatives with CRC, criteria for hereditary CRC not fulfilled:
- One affected first-degree relative increases risk 2-3-fold
- Two or more affected first-grade relatives increase risk 4-25-fold
- Index case <45 years increases risk 3-9-fold
- Familial history of colorectal adenoma increases risk 2-fold
Hereditary CRC (5-10%)
Polyposis-syndromes:
- Familial adenomatous polyposis (FAP)
- Gardner’s syndrome
- Turcot’s syndrome
- Attenuated adenomatous polyposis coli
- Flat adenoma syndrome
Hereditary non-polyposis colorectal cancer (HNPCC)(Lynch syndrome)
Hamartomatous polyposis syndromes:
- Peutz-Jeghers syndrome
- Juvenile polyposis syndrome
- Cowden syndrome
Adapted from Weitz et al 11
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1.3 Molecular carcinogenesis
CRC evolves through a stepwise accumulation of genetic and epigenetic events, which 
lead to the transformation of the normal colonic mucosa into invasive cancer. Most CRCs 
develop from preexisting adenomas that transform into malignant lesions in a process 
estimated to take about 10-15 years 13. The course of the disease varies depending on 
polyp’s characteristics. The presence of multiple adenomas (>3), large size adenomas 
(>1cm in diameter), adenomas with villous change, and adenomas with high grade 
dysplasia, predispose for high risk CRC 14. Recently, a specific subtype of adenomas, 
the serrated adenomas were described, showing a distinct pattern of morphological and 
molecular changes in their transformation process (see section 1.3.1.4) 15.
1.3.1 Carcinogenesis pathways for CRC development
The first model for CRC carcinogenesis was proposed by Fearon and Vogelstein in 1990 16 
(Box 1). In this initial model, there are three important features: i) colorectal neoplasia 
arises from the sequential mutation of oncogenes, leading to their activation, coupled to 
an inactivating mutation of tumor suppressor genes, ii) mutation of at least 4-5 genes is 
necessary for cancer to develop and iii) the accumulation of molecular alterations rather 
than their order is responsible for determining the biologic behavior of the tumor. In the last 
two decades, other molecular pathways contributing to CRC carcinogenesis have been 
described (Box 1). The Chromosomal Instability (CIN), Microsatellite Instability (MSI), and 
the CpG Island Methylator (CIMP) pathways, represent the three main molecular pathways 
that have been recognized. More recently, the serrated pathway, a fourth mechanism for 
CRC carcinogenesis, has been described. Based on tumor features related to the previous 
mentioned pathways, a molecular classification of colorectal carcinomas has been 
proposed (Box 2). 
1.3.1.1 Chromosomal instability pathway (CIN)
Cromosomal instability accounts for 65-70% of sporadic CRC. It is characterized by 
gain or loss of whole chromosomes or chromosomal regions harboring genes relevant 
for the process of colorectal carcinogenesis 13,17. The main causes of CIN are defects in 
chromosomal segregation during mitosis, which finally originate aneuploidy (imbalance in 
chromosome number), telomere dysfunction, or defects in the mechanisms responsible for 
DNA damage response 18. Chromosomes 1, 5, 8, 17 and 18 have the highest frequency of 
allele loss, and common altered cancer genes by chromosomal gains or losses are VEGF, 
MYC, MET, LYN or PTEN 19. The most common single genetic alterations are mutations in 
the APC or KRAS genes 13. 
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Adapted images from: Fearon and Vogelstein 16; Markowitz and Bertagnolli 23.
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1.3.1.1.1 KRAS (12p12)
The KRAS proto-oncogene encodes a GTP-binding protein and is mutated in 30-60% of 
CRC and large adenomas 20. The KRAS product is involved in signal transduction and, 
when mutated, becomes constitutively activated, affecting cellular pathways such as cell 
growth, differentiation, survival or cell motility, among others. 
1.3.1.1.2 APC (5q21)
APC is a tumor suppressor gene, which product has different cellular roles such as the 
control of cell division, cell-cell adhesion or cell migration. It belongs to the canonical Wnt 
pathway, where APC protein forms a complex with β-catenin, axin, and GSK3 (Glycogen 
synthase kinase 3). Loss of both gene alleles is a requisite for APC loss of function 
(Knudson’s two hit hypothesis 21), which leads to the deregulation (constitutive activation) 
of the Wnt pathway by progressive accumulation of cytoplasmic β-catenin, affecting cell 
proliferation, angiogenesis or apoptosis 22. 
1.3.1.1.3 P53 (17p13)
P53 is a tumor suppressor transcription factor that activates genes involved in cell cycle 
arrest, apoptosis, senescence, autophagy, and cellular metabolism. P53 also mediates cell 
adaptation to different kinds of stress or external insults. Loss of P53 protein function leads 
to a deregulation of DNA damage control mechanisms 17,23.
1.3.1.1.4 SMAD2, SMAD4 and DCC (18q21.1)
SMAD2 and SMAD4 proteins are involved in the TGF-β pathway, key for the regulation 
of cellular growth as well as apoptosis 18. Loss of SMAD proteins activation occurs in 
approximately 10% of CRCs 24. DCC (Deleted in colorectal cancer) is a tumor suppressor 
gene that encodes for a transmembrane receptor of the IgG superfamily for netrins, 
molecules involved in axon guidance and developed of the nervous system 23. DCC protein 
also induces apoptosis through Caspase-3 activation, in the absence of its ligand netrin-1, 
process that fails after DCC mutation (inactivation) 25,26. 
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1.3.1.2 Microsatellite Instability pathway (Mutator pathway)
Microsatellites are short repeat nucleotide sequences that are spread all over the genome 
and are susceptible to errors during the process of DNA replication. The DNA mismatch 
repair system (MMR) is the responsible for recognizing and repair errors during the process 
of replication, and its inability to perform this task efficiently, transduces into the appearance 
of microsatellite instability (MSI). Genes involved in the MMR system include MSH2, MLH1, 
MSH6, PMS2, MLH3, MSH3 or PMS1. MSI is divided into MSI-high or MSI-low, depending 
on the number of genes altered from a total of five selected markers 27. MSI-high is defined 
by instability of at least two genes, while MSI-low is considered when instability is detected 
in only one gene. When no instability is detected, tumors are considered microsatellite 
stable or MSS. MSI was first described linked to the presence of HNPCC. Sporadic CRC 
is frequently linked to the hypermethylation silencing of MLH1 28, and usually appears 
combined to the presence of MSI in at least one other MMR gene, and thus considered MSI-
High 29,30. MLH-1 loss of expression in sporadic CRC is usually detected in sessile serrated 
adenomas, reason why these tumor types are not often included in the microsatellite 
instability pathway (Box 2). 
Adapted from Cunningham et al 10
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1.3.1.3 CpG Island Methylator pathway (CIMP)
DNA methylation confers a gene expression regulation mechanism, which does not imply 
modifications in the DNA nucleotide sequence, termed epigenetics. Methylation of DNA 
occurs at cytosine bases when cytosine (C) and guanosine (G) are located in a dinucleotide 
pair, i.e. CpG. Repetitive series of CpG dinucleotides are often located together in particular 
regions of gene promoters, named CpG islands. Promoter methylation interrupts gene 
expression by directly inhibiting transcription factor binding, and also by influencing histone 
acetylation and thus accessibility of the gene to the necessary transcriptional machinery 31. 
The expression of some genes involved in CRC carcinogenesis was found to be repressed 
by promoter hypermethylation (APC, MCC, MLH-1 or MGMT) 13.
A panel of markers has been proposed to classify colorectal cancers into well-defined subsets, 
based on their gene methylation status. This panel includes five genes (CACNA1G, IGF2, 
NEUROG1, RUNX3 and SOCS1) 32. CpG Island Methylator phenotype (CIMP+ or high) is 
defined when at least three of the mentioned markers are methylated (CIMP- or low, when 
two or less methylated genes are present). CIMP high accounts for approximately 15-20% of 
sporadic CRC and usually display common features 13,17,23. 
1.3.1.4 Serrated pathway
Until the late 1990s, colorectal polyps where generally divided into two major subtypes: 
hyperplastic and adenomatous polyps, with this last type proposed as the main precursor of 
colorectal cancer [Fearon and Vogelstein model 16 (Box 1)]. Hyperplastic polyps were considered 
non-malignant lesions with little clinical relevance 33. However, after several clinical observations, 
hyperplastic polyps were progressively associated with an elevated risk for CRC development 34-36. 
In 1990 Longacre and Fenoglio-Preiser first used the term “serrated adenoma” to describe a 
subset of hyperplastic polyps associated with colorectal carcinogenesis 37.
Serrated polyps form a heterogeneous group of colorectal lesions that includes Hyperplastic 
polyps (HP), sessile serrated adenomas (SSA) and traditional serrated adenomas (TSA) 
(Figure 3) 15. Serrated polyps morphologically differ from colorectal adenomas in the presence 
of a “serrated” morphology: saw tooth-shaped infoldings of the surface and crypt epithelium, 
caused by hypermaturation of the gland epithelium due to low extent of cell loss by apoptosis 
(Figure 3). 10% of all CRCs are proposed to arise from serrated polyps 38. 
Recent genetic analyses of serrated lesions have proposed the serrated pathway as a main 
route leading for CRC. However, the genetic alterations occurring in this pathway are not well 
clarified and there is great variability in the frequency of molecular changes described 15,39-41, 
although the most common genetic alterations involve BRAF and KRAS mutations (Box 2).
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Figure 3: Representative hematoxilin & eosin stainings for different types of serrated polyps. 
A) An hyperplastic polyp with serrated glands limited only to the upper one-half of the crypt. 
B and C) Sessile serrated adenomas showing abnormal architectural features such as L-or-T-
shaped crypts, and serrations that extend all the way to the crypt base. D and E) Traditional 
serrated adenomas showing a serrated appearance with crypt lumens lines by tall columnar cells 
with enlarged, crowded and hyperchromatic nuclei. Adapted from Noffsinger A.E. et al 30.
1.3.2. Mouse models for colorectal carcinogenesis
The development of experimental models that mimic the molecular pathways behind CRC 
carcinogenesis has been crucial for its better understanding. In this respect, mouse models 
closely emulate many aspects of the human disease counterpart, recapitulating some 
of the genetic lesions underlying sporadic or hereditary forms of CRC. Two main CRC 
mouse models have been developed to this regard, genetically engineered and chemically 
induced, which basically differ on the methodology used for the generation of colorectal 
tumors.  
1.3.2.1 Genetically engineered CRC mouse models
Genetically Engineered Mouse Models (GEMMs) have been the basis for the study of 
hereditary CRC and, at the same time, for the elucidation of the role played by some of the 
genes involved in the development of sporadic CRC.  
The first model for FAP, termed Min (multiple intestinal neoplasia) mouse, was developed 
Currently, some ambitious projects are being carried out, with the aim of gaining a deeper 
understanding of cancer genomics to improve the global management of cancer patients. 
Of particular interest is The Cancer Genome Atlas (TCGA), driven by the National Human 
Genome Research Institute (U.S). Interestingly, recent results from this project have shown that 
a specific subset of 24 genes was significantly mutated in patients with CRC, proposing, among 
others, ARID1A, SOX9 and FAM132B/WTX as potential driving genes for CRC 42. 
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by random mutagenesis, and carried a truncation mutation at codon 850 of the Apc gene 43. 
Min mice developed up to 100 polyps in the small intestine in addition to colon tumors. 
Later models specifically targeting the Apc gene by directed mutagenesis were developed. 
Apc truncation at codon 716 (ApcΔ716) 44 or 1638 (Apc1638N) 45, resulted in the formation 
of polyps in the small intestine. Apc1638N mice displayed a long lifespan (a year or more), 
perhaps because of the fact that, on average, each mouse developed only 3-5 adenomas/
carcinomas. However lifespan for ApcΔ716 mice was much reduced because of the formation 
of a large number of gastrointestinal adenomas. Genetic models bearing mutation in 
additional genes (Cdx2 46 or Smad4 47), in combination with ApcΔ716, have shown to increase 
the rate of polyps and tumor formation as well as tumor invasiveness. Mutations in the beta-
catenin gene, whose stability is regulated by Apc, caused the formation of up to 3000 polyps 
in the small intestine, reinforcing the role of the Apc gene in the development of FAP 48. 
Regarding HNPCC, mouse models bearing alterations in the Msh2 and Mlh1 genes 
have been developed. Msh2 deficient mice developed gastrointestinal adenomas 
and carcinomas. However, 50% of the animals died before the age of 6 months (when 
the formation of intestinal tumors can be observed) due to the development of T-cell 
lymphomas, suggesting the involvement of Msh2 in lymphoblastic lymphomas 49. Mlh1 
knockout mice displayed a reduced survival similar to Msh2 -/- animals, also due to the 
presence of T-cell lymphomas and small intestinal tumors 50. The combination of Mlh1 
and Apc1638N mutant mice dramatically increased the number and invasiveness of intestinal 
tumors, consequently decreasing mice survival 50.
Other mouse models have been developed with mutations in additional genes, not 
directly implied in hereditary CRC. Mice bearing mutations in the Tgfβ1 gene dramatically 
accelerated the progression of colorectal adenocarcinomas 51. Mutated K-ras transgenic 
mice represent one of the most important models for sporadic colorectal cancer. Colon-
specific expression of activated mutant K-ras (K-rasG12D) resulted in the development of 
single or multiple lesions recapitulating the stages of tumor progression 52,53. 
1.3.2.2 Chemically induced CRC models
As the spontaneous incidence of CRC in mice is low (1-4%), many chemicals have 
been used to induce CRC. Some of this carcinogens include dimethyhydrazine (DMH), 
azoxymethane (AOM), dextran sulfate sodium (DSS), 2-amino-1-methyl-6-phenylimidazol, 
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) or 3,2’-dimethyl-4-aminobiphenyl (DMBA). 
Dosage and treatment duration, as well as the route of administration, determine the 
effectiveness of these drugs for the formation of colorectal tumors. Moreover, it has been 
shown that the genetic background of the mice plays a significant role in the development 
of tumors when using this approach 54. 
32
Chapter I
1.4 Screening, diagnosis and staging
1.4.1 Screening
Colorectal cancer constitutes a disease characterized by a long preclinical stage, with the 
progression from early adenoma to invasive cancer taking years 55. Moreover, and despite 
advances in treatment, 40-50% of patients presenting with symptomatic CRC eventually die 
of metastatic disease 56. These characteristics of CRC make it more suitable for population 
screening than any other malignancy. 
1.4.1.1 Conventional CRC screening tests
Current CRC screening tests can be broadly differentiated as early detection tools or 
cancer-prevention tools, depending on their modes of action 57. Cancer prevention tools 
constitute tests that can find both colorectal polyps and lesions that have progressed to 
a more advanced stage. Early detection tools constitute a series of methodologies that 
are only able to detect CRC, but they are not suitable for the detection of possible pre-
malignant lesions. Table 2, summarizes conventional CRC screening tests. 
Fecal occult blood test (FOBT) and Fecal immunochemical test (FIT) are the two main early 
detection tools available 58. FOBTs can be used to quantitatively detect microscopic amounts 
of haem in the stool. FITs detect human globin by means of an antibody-based assay, 
detecting also microscopic amounts of material in the stool, as FOBTs 57-59. Advantages 
and disadvantages of early detection tools are summarized in Table 2, lower section. 
These techniques provide fast and inexpensive results, however, they are being replaced 
by imaging techniques, as a positive test does not prove a definitive diagnosis. Cancer 
prevention tools mainly include imaging techniques that allow visualization of the inner part of 
the intestine for the detection of polyps or more advanced lesions (Figure 4). In some cases, 
these techniques allow the removal of existing lesions in the same procedure 57. Advantages 
and disadvantages of the main cancer-prevention tools are summarized in Table 2, upper 
section. 
Related to the early detection of CRC, the local government of Galicia has recently 
implemented a screening program for population considered at risk (women and men 
between 50 and 69 years), based on the use of FOBT. This type of strategies are of key 
importance for the reduction of CRC-related mortality rates, especially in regions like this, 
where factors including dietary habits and the presence of an ageing population, increase 
the risk for CRC development. 
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Table 2. Conventional CRC screening tests
Screening test Advantages Disadvantages
Cancer-prevention tools
Flexible sigmoidoscopy
-Fairly quick and safe
-Sedation not required
-Does not require a specialist
-Done every 5 years
-Images only 1/3 of the colon
-Can miss small polyps
-Can’t remove all polyps
-Small risk of bleeding, infection 
of bowel tear
-Colonoscopy will be needed if 
abnormal
Colonoscopy
-View of the entire colon
-Can biopsy and remove polyps
-Done every 10 years
-Can diagnose other diseases
-Can miss small polyps
-Full bowel preparation needed
-Sedation needed
-Small risk of bleeding, infection 
of bowel tear
Double-contrast barium 
enema (DCBE)
-View of the entire colon
-Relatively safe
-Done every 5 years
-No sedation needed
-Can miss small polyps
-Full bowel preparation needed
-Cannot remove polyps during 
testing
-Colonoscopy will be needed if 
abnormal
CT-colonography
(virtual colonoscopy)
-Fairly quick and safe
-View of the entire colon
-Done every 5 years
-No sedation needed
-Can miss small polyps
-Full bowel preparation needed
-Cannot remove polyps during 
testing
-Colonoscopy will be needed if 
abnormal
Early detection tools
Fecal occult blood test 
(FOBT)
-No direct risk to the colon
-No bowel preparation
-Sampling done at patient’s 
home
-Inexpensive
-May produce false-positive 
results
-Should be done every year
-Colonoscopy will be needed if 
abnormal
Fecal immunochemical 
test (FIT)
-No direct risk to the colon
-No bowel preparation
-Sampling done at patient’s 
home
-Fairly inexpensive
-May miss many polyps and 
some cancers
-May produce false-positive 
results
-Should be done every year
-Colonoscopy will be needed if 
abnormal
Data from Kuipers et al 57
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1.4.1.2 Other screening modalities
1.4.1.2.1 Imaging techniques
CRC screening methodologies are continuously improving, with the aim of lowering patient 
burden and enhancing neoplasia detection. In the last years, methods that include modifications 
of conventional endoscopes to improve visualization have been developed 60,61. An interesting 
recent technique is the use of a colon-capsule endoscopy 62,63. This system consists in an 
indigestible capsule with a 172-degree video imager at each end. The capsule is moved 
through the colon by peristalsis and transmits images to an external data recorder carried by 
the screenee. This type of imaging requires performing certain previous clinical procedures 
to maximize the quality of the final images, and its current costs represent a limitation for 
the widespread of the capsule in screening programs 64. 
Figure 4: Representative colonoscopy images. A) Normal intestinal wall. B) Numerous polyps 
characteristic of HNPCC. C) A pedunculated adenoma with signs of minimal bleeding at the base of 
the stalk. D) Advanced colorectal carcinoma.
1.4.1.2.2 Molecular markers
Apart from the direct bowel observation by different imaging procedures, several indirect 
molecular markers have been explored as screen-detection tools for CRC and precursors 
of cancer. These markers can be measured in serum, tissue or stools, and they mainly 
reflect the mechanism of exfoliation of neoplastic cells and secretion of mucus containing 
abnormal glycoproteins in CRC 57. Serum markers include, for example, the analysis of the 
methylation status of septin-9 (SEPT9) because its ability to discriminate between normal 
and cancerous tissues 65. The expression analysis of MMP7 (Matrix metalloproteinase-7) 
and PTGS2 (prostaglandin G/H synthase 2) from RNA has also been assessed 66. Some 
proteins have been analyzed in the stool (calprotectin or carcinoembrionic antigen, CEA) 67. 
However, evidences from all the previous mentioned markers are still in an initial step, and 
larger validation studies should be conducted to delineate its value as screening markers.
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1.4.2 Signs and symptoms
Most colorectal cancers are diagnosed after the onset of symptoms which mainly include 68:
- A change in bowel habits, such as diarrhea and constipation, that lasts for 
more than a few days.
- Rectal bleeding, dark stools or blood in the stool.
- Abdominal pain
- Weakness and fatigue.
- Unintended weight loss.
1.4.3 Diagnosis and staging
CRC is definitively diagnosed on the basis of the results of colonoscopy or sigmoidoscopy, followed 
by tumor biopsy examination 10. A newly diagnosed case of CRC undergoes a complete check, in 
order to determine cancer extent. Physical examination and a complete colonoscopy (to rule out 
metachronous tumors) are performed, and a computed tomography (CT) of the chest, abdomen, 
and pelvis are carried out to identify metastatic disease (Figure 5). Ultrasounds and Magnetic 
Resonance Imaging (MRI) can also be used to determine the extent of disease. Positron 
Emission Tomography (PET) with the 18-fluoro-2deoxy-D-glucose (FDG-PET) can be used 
to rule out extrahepatic spread (Figure 5). Based on all the obtained parameters, using the 
above-mentioned methodologies, staging is described according to the TNM (tumor, node, 
metastases) system 69 (Table 3) (Figure 6). An accurate tumor staging results critical for the 
management of disease, as the choice of an appropriate treatment is based on it.
Figure 5: Detection of 
metastatic lesions in CRC 
by imaging techniques. 
A) Liver and B) lung lesions 
detected by computed 
tomography.     C) Metastatic 
liver nodes detected by FDG-
PET
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Figure 6: Colorectal 
cancer stages. As 
colorectal cancer 
progresses from 
stage 0 “carcinoma 
in situ” to stage 
IV, cancer cells 
sequentially grow 
through the layers 
of the rectum wall, 
and spread to lymph 
nodes and distant 
organs in the most 
advanced stages.
Table 3. TNM classification of colon cancer
T=primary tumor
TX: primary tumor cannot be assessed.
T0: no evidence of primary tumor.
Tis: carcinoma in situ: intraepithelial or invasion of lamina propria
T1: tumor invades submucosa
T2: tumor invades muscularis propria
T3: tumor invades through the muscularis propria into subserosa or into peritonealised pericolic 
or perirectal tissues
T4a: tumor penetrates the surface of the visceral peritoneum
T4b: tumor directly invades or is histologically adherent to other organs or structures
N=regional lymph nodes
NX: regional lymph 
N0: no regional lymph node metastasis
N1a: metastasis in one regional lymph node
N1b: metastasis in two to three regional lymph nodes
N2a: metastasis in four to six regional lymph nodes
N2b: metastasis in seven or more regional lymph nodes
M=distant metastasis
MX: distant metastasis cannot be assessed
M0: no distant metastasis
M1a: distant metastasis to one site
M1b: distant metastasis to more than one site
Staging
Stage I                (T1/T2, N0, M0)
Stage IIA  (T3, N0, M0)
Stage IIB  (T4a, N0, M0)
Stage IIC  (T4b, N0, M0)
Stage IIIA  (T1/T2, N1, M0)
Stage IIIB (T3/T4, N1, M0)
Stage IIIC  (Any T, N2a/N2b, M0)
Stage IVA  (Any T, Any N, M1a)
Stage IVB  (Any T, Any N, M1b)
Adapted from Cunningham et al 10
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1.4.4 Prognostic factors and biomarkers
A prognostic factor is defined as a measurement of a disease-related parameter, through 
a direct or indirect observation, that is associated with the clinical outcome of the patient 
in the absence of therapy or with the application of a standard therapy that patients are 
likely to receive 70. The American Joint Committee on Cancer (AJCC) has established 
a colorectal working group, which has evaluated the role of biologic, genetic, molecular 
and other nonanatomic factors with prognostic value in CRC 71. Prognostic factors are 
classified into five different categories (I, IIA, IIB, III and IV) (Table 4) based on the 
existence of conclusive evidences about their effectiveness, with category I including 
the best characterized factors, currently used in routine clinical patient management, 
and category IV including factors that have been studied but didn’t show prognostic 
significance. Examples of prognostic factors included in each category, are summarized 
in Table 4, right panel.
To date, a limited number of factors have shown the necessary prognostic evidences 
to be considered as clinically relevant, and only tumor extent related features are 
considered of strong prognosis value. The presence of carcinoma in situ, a malignancy 
that has not yet penetrated the basement membrane of the epithelium to invade the 
underlying lamina propria, is considered a major good prognosis factor. Moreover, the 
presence of distant metastasis or cancer spread to regional lymph nodes constitute two 
important factors that determine patient outcome 72. The evaluation of serum CEA is the 
most accepted and frequently used tumor prognostic biomarker in CRC, partly due to its 
relatively inexpensive and easy detection. The main use of CEA in CRC is in surveillance 
following curative resection for primary cancer 73,74,  where CEA levels higher than 5.0ng/ml 
have an adverse impact on patient prognosis, independent of tumor stage 75. 
In the last years, alternative biomarkers have been proposed in order to evaluate patient 
prognosis more accurately. In this regard, the analysis of Circulating Tumor Cells (CTCs), 
tumor cells that have shed into the circulation from the primary tumor, has become of 
a great interest. CTCs are proposed as a major vehicle for tumor dissemination and 
metastasis formation, so it is reasonable to think that their presence in the blood could 
provide information about disease status, separating patients with different prognosis 
depending on the existence of CTCs or not (and if yes, their number) in patient’s blood. In 
fact, several works have confirmed the validity of CTC count as an independent prognostic 
factor, mainly in metastatic CRC (mCRC) 76-81. Another promising biomarker to evaluate 
patient outcome is the analysis of circulating tumor DNA (ctDNA), DNA fragments mainly 
originated from apoptotic or necrotic tumor cells that discharge their DNA into the blood 
circulation 82.  Elevated concentrations of cell-free ctDNA fragments have been found to 
be associated with unfavorable outcome in some clinical studies 82,83. Moreover, ctDNA 
sequencing offers the possibility to assess tumor-specific mutations without the need of 
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Table 4. Classification of prognostic markers in CRC.
Category Definition Prognostic factors included
Category I
Well supported by literature, 
generally used in patient 
management, and of sufficient 
importance to modify TNM stage 
groups
-Pathological assessment of tumor 
extent (pT)
-Regional lymph node metastases (pN)
-Presence/absence of blood/lymphatic 
vessel invasion
-Residual tumors
-Elevated serum CEA
Category IIA
Extensively studied biologically 
and/or clinically. Sufficient to be 
noted in a pathology report
-Presence of residual tumor after 
resection
-Radial margins
-Histologic grade
-Tumor border configuration
Category IIB Well studied but not sufficiently established
-Lymphocytic infiltration of tumor or 
peritumoral tissue
-Histologic types
-Tumor tissue molecular markers
 -18q/DCC loss (LOH)
 -mutated KRAS
 -MSI
 -Thymidylate synthase (TS) high
 -p27 low
 -Bcl-2 loss
 -p53 inactivation
Category III Less well studied and not yet sufficiently established
Perineural invasion, microvessel 
density, tumor cell associated proteins 
or carbohydrates, peritumoral fibrosis, 
peritumoral inflammatory response, 
focal neuroendocrine differentiation, 
nuclear organizing regions, 
proliferation indices.
Category IV
Studied and shown to have 
no consistent prognostic 
significance
Tumor size and histologic tumor type
Data from López-Gómez et al 72
tissue biopsy, making easier the evaluation of tumor characteristics 83. Both CTCs and 
ctDNA analysis have been proposed as new promising biomarkers for patient prognosis 
in CRC, providing valuable information from a simple and non invasive blood sample, 
reason why their use has led to the occurrence of the term “liquid biopsy”. Detailed 
information of the clinical value of CTCs can be found in introduction section 3.
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1.5 Treatment
CRC treatment encompasses different strategies that are applied or not mainly depending 
of the grade of tumor extent, reason why an adequate staging is crucial for the selection of 
the most suitable therapy. 
1.5.1 Surgery
Surgery represents the only curative modality for localized CRC and also provides a potentially 
curative option for selected patients with limited metastatic disease in liver and/or lung. In 
many cases, even in those who cannot be cured by surgery, this procedure benefit them 
through palliation of symptoms such as obstruction and bleeding from the primary tumor 84. 
When CRC is found at a very early stage, usually in situ carcinomas, local excision of the 
primary tumor can be applied. Total resection of the tumor should be done in cases of larger 
tumor extent. 
1.5.2 Adjuvant CRC therapy
Despite improvements in CRC surgery, many patients still have a high risk of tumor 
recurrence. To reduce those risks, adjuvant treatment is used in a subset of patients suffering 
from non-disseminated disease. Adjuvant therapy corresponds to any given treatment that 
is administered to the patient after the main therapy, which is normally surgery is this kind of 
patients. 
For stage III patients, adjuvant therapies are mainly based in the use of 5-Fluorouracil (5-FU), 
alone or in combination with other agents 85. For example, 5-FU plus Leucovorin (LV) has 
demonstrated an improvement in patient outcome 86. Adjuvant therapy is also used for stage 
II CRC patients. 
In the last years, the combination of targeted therapies with classic chemotherapeutic agents 
has gained importance. The introduction of monoclonal antibodies that target the Epidermal 
Growth Factor Receptor (EGFR) (Cetuximab or Panitumumab) or Vascular Endothelial 
Growth Factor (VEGF) (Bevacizumab), has expanded the agents available for use in adjuvant 
setting 85. However, these agents have not demonstrated enough clinical utility when applied 
in the adjuvant setting so far, and their main field of application is in metastatic CRC (see 
section 1.5.4). 
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1.5.3 Neoadjuvant CRC therapy
A neoadjuvant therapy is a treatment given as a first step, to shrink the tumor before the 
main treatment, usually surgery, is given. Neoadjuvancy is not considered for non-metastatic 
stages of CRC, as surgery is usually the first treatment, and is in rectal cancer where this 
kind of therapies are generally applied 87. However, in resectable metastatic CRC disease, 
similar therapeutic regimes to those used for adjuvancy in non-metastatic CRC are being 
used. FOLFIRI scheme (Irinotecan + Leucovorin + 5-FU), and combinations with targeted 
therapies are also used in this setting. 
1.5.4 Metastatic CRC treatment
The majority of patients with metastatic colorectal cancer (mCRC) cannot be cured, 
although a subset with hepatic and/or lung metastases are potentially curable with surgery. 
For the rest, treatment is palliative and generally consists of systemic therapy, which has 
demonstrated to improve both progression-free survival (PFS) and overall-survival (OS) 
when compared to patients receiving only supportive care 88,89. 
For advanced colorectal cancer (stage IV), first line chemotherapy is mainly based in the use 
of fluoropyrimidines (5-FU or capecitabine), which represent the basis of current common 
treatments. Other drugs, such as Irinotecan (a topoisomerase I inhibitor) or oxaliplatin (a 
second generation platinum derivative), have demonstrated significant activity in mCRC 89-91. 
However, they are not commonly used as single agents, as their combination with 5-FU or 
capecitabine significantly improve their effectiveness 89,92,93. 
The election of more or less aggressive therapies is normally guided by patient’s performance 
status (PS). PS is categorized using an scale defined by the Eastern Cooperative Oncology 
Group (ECOG), that attempts to quantify patient’s general well-being 94 (Table 5). First-line 
refractory patients (with good performance status) are generally proposed for a second line 
therapy based of a different drug combination.
Current therapeutic approaches generally include the combination of classic chemotherapies 
with modern biological agents that target specific signaling pathways commonly altered in 
CRC. The heterogeneous nature of cancer means that personalized medicine (i.e. tailoring 
therapy to an individual patient) is a promising approach for maximizing efficacy and 
minimizing the toxicity of treatment. This kind of therapeutic strategies also reduce therapy-
related costs, as treatment is only given to those patients likely to benefit. 
41
General Introduction
Table 5. ECOG performance status scale. 
Grade Characteristics
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry work of a light sedentary nature.
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.
5 Dead
Data from Oken et al 94
Two main signaling pathways are currently being targeted using biological agents: Vascular 
Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR). 
1.5.4.1 Agents targeting VEGF: Bevacizumab
Bevacizumab (Genentech, San Francisco, U.S) is a recombinant, humanized, monoclonal 
antibody that blocks the activity of VEGF, a central mediator of tumor-related angiogenesis 95. 
When used in combination, Bevacizumab improves PFS compared with chemotherapy 
alone 96,97, preferably when applied with irinotecan-based regimens 98. However, and 
despite much research, is still poorly understood which patients/tumors characteristics 
are best treated with anti-angionenics, and no validated predictive markers (markers that 
indicate which patients will respond to a given therapy) are currently available 99. 
1.5.4.2 Agents targeting EGFR: Cetuximab and Panitumumab
EGFR is overexpressed in about 70% of patients with mCRC and has been considered a poor 
prognostic factor 100. Panitumumab (Amgen, Thousand Oaks, U.S) and Cetuximab (ImClone, 
Branchburg, U.S) are two monoclonal antibodies targeting active EGFR, normally administered 
in combination with classical chemotherapy drugs, showing improved efficacy 101. Molecular 
events such as overexpression or mutation of genes involved in the EGFR signaling 
pathway (for example KRAS, NRAS or BRAF) identify patients that are likely to respond to 
anti-EGFR drugs 95,102 (see section 1.5.5).
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1.5.4.3 New therapeutic agents
Considerable advances in the development of new mCRC therapeutic approaches have 
been achieved in the last years, as evidenced by the increasing number of molecules (usually 
monoclonal antibodies or small inhibitors) available for mCRC patient’s treatment 89. Some 
of the new therapeutic agents, currently used in the clinics, or under testing in clinical trials 
are summarized in Table 6.
Table 6. Summary of new therapeutic agents for mCRC treatment
Molecule Type Target
Agents being used in the clinical setting
Aflibercept Recombinant protein VEGF
Regorafenib TKI RTKs
Agents under clinical testing
Cediranib TKI VEGF
Mapatumumab MoAb TRAIL-receptor
IGFR Inhibitors MoAb and TKI IGFR
AMG102 MoAb HGF
Vismodegib Small-Inhibitor Hedgehog Signaling
Vemurafenib Small-Inhibitor Mutated BRAF
AZD6244 Small-Inhibitor MEK
Olaparib Small-inhibitor PARP
Dasatinib TKI SRC
Abbreviations: TKI: Tyrosine Kinase Inhibitor; MoAb: Monoclonal Antibody; RTKs: Tyrosine Kinase Receptors
Data from López-Gómez et al 89
1.5.5 Predictive markers
One of the main problems of CRC therapies is the existence of toxicity-related side 
effects, which are sometimes reason enough to stop a the administration of a therapy. 
Moreover, actual targeted therapies are sometimes directed to a very specific molecule. 
All this makes necessary the existence of predictive markers that allow the identification 
of subpopulations of patients who are more likely to respond to a given therapy, avoiding 
unnecessary therapy-related toxicities in patients with low response probabilities. 
In CRC one of the best-studied examples of a predictive biomarker is the KRAS gene 
mutational status for patients treated with anti-EGFR antibodies. KRAS mutation originates 
a constitutively active GTPase, which will transmit signals to its downstream effectors 
irrespective of the presence of EGFR ligands. Lievre et al showed for the first time that 
KRAS mutations in mCRC patients are a predictor of resistance for Cetuximab therapies 
and are associated with worse prognosis 103. After this first study, the association of KRAS 
mutations and resistance to anti-EGFR treatment, either Cetuximab or Panitumumab, 
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was confirmed in large, retrospectively evaluated phase III studies 104,105. More recently, 
activating mutations in RAS (either KRAS or NRAS) have been suggested as negative 
predictive biomarkers for anti-EGFR therapy 102. These clinical data is supported by 
the biological similarities existing between KRAS and NRAS, together with the fact that 
mutations in both genes results in increased levels of guanosine triphosphate-bound RAS 
proteins 106. However, HRAS, the third member of the RAS family, is rarely mutated in CTC, 
which discards its association with this type of targeted therapies. 
Other molecular markers have been identified and validated as predictive markers for a 
specific therapy, indicating the probability of tumor response, but also giving information 
about other therapy-related features, like toxicity. Table 7 shows an overview of current 
predictive molecular markers in CRC. Not included in the table, but of an increasing interest 
is the analysis of CTCs, especially for patients with disseminated disease. Until now, CTCs 
have been used mainly as an indicator of patient prognosis, based on the CTC number 
at baseline, e.g. before therapy. Several studies have focused now on the potential role 
of CTCs as a predictive biomarker. CTC number changes along treatment were found 
to be related with therapy effectiveness in CRC, mostly in metastatic disease. 76,77,108-112. 
Moreover, CTCs offer the possibility of analyzing particular gene or protein alterations, 
usually related to therapy response when assessed in the primary tumor, which provides 
an opportunity for non-invasive and real-time monitoring of treatments 113,114. Detailed 
information about the utility of CTCs as therapy response predictive markers can be found 
in introduction section 3.
Table 7. Predictive biomarkers in CRC
Marker Alteration Predictive for:
Thymidilate-Syntase (TS) Increased expression Decreased 5-FU response
Dihydropyrimidine-
dehydrogenase (DPD) Decreased DPD activity
Increased 5-FU toxicity
Increased 5-FU response 
UDP-glucuronosyl 
transferase 1A1 (UGT1A1) Decreased UGT1A1 activity
Increased Irinotecan-induced 
neutropenia
ERCC1 Decreased ERCC1 expression Increased oxaliplatin response and survival
RAS (KRAS and NRAS) Constitutive GTPase activation Resistance to anti-RGFP MoAb’s therapy
BRAF Constitutive activation Decreased survival
COX2 Reduced promoter activity Increased Cetuximab PFS
IL-8 VEGF Increased VEGF expression Increased recurrences
Abbreviations: 5-FU: 5-Fluorouracil; MoAb’s: Monoclonal Antibodies; 
Adapted from Winder et al 107
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2. Cancer metastasis. Focus on colorectal cancer
2.1 The metastatic cascade
Whereas surgical resection and adjuvant therapy can cure well-confined primary CRC 
tumors, metastatic disease is largely incurable because of its systemic nature and the 
resistance to current therapeutic agents. This explains why more than 90% of mortality 
from cancer is attributable to the existence of metastatic disease 115,116. 
Cancer metastasis has been a focus of innumerable research works for many years. 
However, and although considerable understanding of the process of cancer spreading 
has been achieved, much is still unknown, due to its complexity. Cancer metastases are 
formed following the completion of a succession of cell-biological events (also termed the 
metastatic cascade 121,117) by which epithelial cells in primary tumors are able to invade the 
surrounding stroma, enter the circulation and finally reach a target organ to form a distant 
tumor mass 116 (Figure 7). Many of these events are orchestrated by molecular pathways 
operating within carcinoma cells. Moreover, their interaction with non-tumor stromal cells 
also plays a pivotal role throughout the whole process of metastasis. 
Figure 7: The invasion-Metastasis cascade. During metastatic progression, tumor cells exit their 
primary sites of growth by a process of local invasion and subsequent intravasation into nearby 
blood vessels. After their translocation into the bloodstream, they must survival in the circulation and 
arrest at distant sites for to further escape the circulatory system by extravasation. Micrometastasis 
formation depends on the ability of cancer cells to adapt and thrive in the foreign microenvironments 
of distant tissues. Carcinoma cells are depicted in red. Image from Valastyan et al 121.
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2.1.1 Local invasion
After primary tumor formation and in order to invade the tumor surrounding stroma, cancer 
cells must first breach the basement membrane (BM), a specialized extracellular matrix (ECM) 
that separates the epithelial tumor compartment from the neighbor stromal cells 116,118,119. In a 
non-tumor situation, BM plays a crucial in the maintenance of the epithelial architecture, by 
providing a structural support for the correct alignment and polarization of epithelial cells, a 
key process for the development of a highly organized epithelial tissue 119,120. 
Depending on the tumor type and the surrounding tissue, various patters of invasion can 
be observed 121. Most carcinomas can invade as cohesive multicellular units through a 
process termed “collective invasion”. Alternatively, tumor cells can invade as single cells, 
invasion mechanism evidenced by the presence of isolated and dispersed tumor cells in 
the tumor-adjacent tissues 121,122. 
2.1.1.1 Collective invasion
Collective invasion is characterized by the mainteinance of cell-cell adhesions between 
invading cells, by the continuous expression of adhesion molecules and other components 
of the adhesive apparatus (cadherins, tight junction proteins, adhesion receptors of the 
immunoglobulin superfamily and gap junctions) 121 (Figure 8). To finally penetrate the 
BM, cancer cells must develop the ability of degrading and remodel the ECM, process 
that allows them to break through the surrounding extracellular components. Collectively 
migrating colon cancer cells engage and cluster integrins in anterior protrusions toward 
the ECM and shown elevated expression of specific matrix-metalloproteases (MT1-MMP, 
uPA/uPAR or MMP2) for remodeling the ECM and move towards adjacent tissues 123. The 
morphological organization of collectively invading cells can vary from strands of few cells 
to broad cellular masses, that can migrate as isolated cellular clusters or as invading tip-
like structures, characterized by the presence of one or more leading cells (with actin-
rich invading structures and elevated metalloprotease activity), that guide the invasion of 
the whole group 122. All these invading structures are characterized by the presence of 
well-established cell-cell junctions, supracellular contractility and a high rate of cell-matrix 
adhesions turnover (Figure 8). 
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2.1.1.2 Single cell invasion
One of the main traits that characterized single cell invasion/migration is the complete or 
partial loss of cell-cell contacts. Individual tumor cells may invade via two distinct programs: 
the mesenchymal invasion (protease, stress fiber and integrin-dependent), or the amoeboid 
invasion (integrin-independent, Rho/ROCK-dependent) 124. Mesenchymal invading cells 
frequently display many hallmarks of the Epithelial to Mesenchymal Transition (EMT) 
process (see Box 3), and usually display high levels of cell-matrix adhesion and proteolysis. 
On the contrary, amoeboid invading cells are largely independent of these requirements 
but rely on cortical actomyosin contractility 116,121,125-127. 
A range of intermediate phenotypes were described between single and collective cell 
migration. Single cells can migrate individually, but close enough one from each other, 
and following similar paths, normally imposed by the presence of a chemical gradient or 
by the physical characteristics of the ECM, in an invasion modality termed “multicellular 
streaming” 128. Very weak or no cell-cell contacts were detected in this specific situation 
(Figure 8). Multicellular streaming has been observed in ortothopic breast cancer and 
melanoma models, but not in CRC 122,124,129.
Once invading cells degrade the component of the basement membrane, and migrate 
through it, they reach the stromal compartment where they must coexist with several 
Figure 8: Cancer cell invasion 
modalities. Cancer cell invasion 
patterns include amoeboid 
or mesenchymal single-cell 
migration; multicellular streaming 
with or without weak junctional 
contacts or collective cell 
migration. Although each pattern 
can be described as a different 
process, overlapping cell behavior 
can result in mixed or unstable 
phenotypes. Intensity range of 
proposed properties (from absent 
to strong) is indicated by minus 
and plus signs.
Adapted from Friedl et al 127.
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different tumor-associated cell types (fibroblasts, endothelial cells, adipocytes and bone-
marrow derived cells 130,131). As primary tumor progression proceeds, the stroma becomes 
increasingly “reactive” acquiring typical characteristics of the stroma observed in wound 
healing or inflammation, and these features further enhance the aggressive behavior 
of carcinoma cells 116. For example, stroma fibroblasts (also termed Cancer Associated 
Fibroblasts, or CAFs) can remodel the ECM through enzymes, rendering it more supportive 
of tumor cell invasion 132,133 (Figure 9). Altogether, the specific characteristics of the 
stromal cells contribute to the migration and invasion of cancer cells through the stromal 
compartment towards nearby lymph and blood vessels.
Figure 9: The early steps of metastasis: tumor invasion, dissemination and survival in the 
circulation. In order to disseminate, carcinoma cells need to acquire the capabilities to break down 
the basement membrane, invade into the stroma, enter the bloodstream and manage to survive 
before they can arrest at distant sites and grow into clinically detectable metastases. Examples of 
tumor-stroma crosstalk are illustrated. EC: endothelial cells. Image from Wan et al 138.
2.1.2 Intravasation
The term intravasation refers to the process by which invasive carcinoma cells enter into 
the lumina of tumor associated lymphatic or blood vessels. Although lymphatic spread 
of CRC is routinely observed in human tumors and represents an important prognostic 
marker for disease progression, dissemination via the hematogenous circulation appears 
to represent the major mechanism by which metastatic cells disperse 115. Growing tumors 
need to develop neo-vasculature in order to grow beyond the diffusion limit of preexisting 
blood vessels 134, process that facilitates the escaping of tumor cells from the primary 
tumors through the circulation 115. Moreover, newly formed blood vessels within the tumor 
are characterized by its leaky structure, with not well-established cell-cell contacts between 
endothelial cells, and under continuous reconfiguration, characteristics that are likely to 
facilitate intravasation 135. The molecular mechanisms controlling intravasation remain to 
be well defined. In colon cancer, it has been recently shown that Notch signaling in cancer 
cells can be stimulated by coexisting stromal cells, further enhancing intravasation and 
thus, promotion of metastasis 136 (Figure 9). 
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2.1.3 Survival in the circulation
Once malignant cancer cells have invaded the circulatory compartment, they attain ready 
access to virtually all organs of the body. These circulating tumor cells (CTCs), represent 
carcinoma cells that are en route between primary tumors and sites of dissemination and 
therefore may represent “metastatic intermediates” 116. 
CTCs must be able to survive several stresses, including physical damage from hemodynamic 
shear forces, and immune mediate-killing 115. Carcinoma cells seem to overcome these 
threats through the formation of relative large associations with blood platelets, that protect 
them both from shear forces and facilitates evasion of immune detection 130 (Figure 9). 
Moreover, the lack of integrin-dependent adhesion to ECM components, that is normally 
essential for cell survival, makes CTCs more susceptible of undergoing anoikis (apoptosis 
triggered by loss of anchorage to substratum) 137,138. To this regard, it has been shown that 
brain-derived neurotrophic factor (Bdnf) receptor (trkB) conferred resistance to anoikis in rat 
intestinal epithelial cells 139 (Figure 9). Moreover, in a prostate cancer model, Talin1, a key 
component of the focal adhesion complex, regulated anoikis resistance further promoting 
metastasis formation 140 (see introduction section 4 for further Talin1 information). However, 
the relevance of anoikis in the process of metastasis remains uncertain, as it make take 
mere minutes for a malignant cell departing from a primary tumor to encounter a capillary 
bed and adhere to the vascular wall 115. Due to the large diameter of CTCs (20-30μm), they 
are likely to become trapped in narrow capillaries (≈8 μm) in their first pass through the 
circulation 116 (Figure 10), and if the time that CTCs spend devoid of adhesion is so short, 
anoikis may not be a very significant impediment during metastasis progression. 
2.1.4 Arrest at distant sites and extravasation
Having invaded and endured the circulation, metastatic cells must at some point escape 
the bloodstream to finally colonize a target organ, in a process termed extravasation 115. 
Despite the theoretical ability of CTCs to disseminate to a wide variety of secondary loci, 
clinicians have long noted that individual carcinoma types form metastasis in only a limited 
subset of target organs 141. Particularly in CRC, liver is largely the preferential site for 
metastasis formation, with lung as a frequent, but secondary site. In fact, CRC metastatic 
dissemination seems to follow a stepwise manner in which lung metastasis develops only 
after the formation of considerable liver metastases. This pattern can be explained by the 
anatomical layout of the vasculature, which drain most CTCs through mesenteric circulation 
into the liver 133. This model for CRC dissemination is partially supported by a study showing 
lower number of viable CTCs in the peripheral blood, compared to the mesenteric blood in 
patients with CRC 142. Moreover, carcinoma cells arriving in the liver encounter fenestrated 
sinusoids that are highly permeable even in their normal state and consequently seem to 
pose only minor obstacles to extravasating tumor cells 143. 
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However, tissue-specific arrest of CTCs might not be only a physical process, by which 
CTCs are retained in capillary beds due to size restrictions. Some cells may elude this rapid 
trapping because of their unusual plasticity, enabling then to be lodged in the microvessels 
of more distal organs 116. An alternative hypothesis is that CTCs have predetermined 
predilections to lodge in certain tissues. In fact, entry of CRC cells into the hepatic vasculature 
can initiate a proinflamatory cascade that results in Kupffer cells being triggered to secrete 
chemokines that upregulate vascular adhesion receptors, enabling adhesion of CTCs to 
the microvasculature of the liver 144. Another hypothesis is that tumor cells, either at primary 
sites or in the circulation, can release soluble factors of microvesicles to convert incipient 
metastatic sites into compatible “premetastatic niches” 145,146. For example, melanoma-
derived exosomes have been show to promote metastasis by education of bone marrow 
cells 147, and Tenascin C, a component of the extracellular matrix, produced by breast 
cancer cells in primary tumors, can remodel secondary sites promoting a more permissive 
niche for CTCs implantation 148. 
Metastatic cells can either escape the circulation individually, or considerable growth 
within the intravascular space may occur before target organ colonization 149 (Figure 
10). To escape the circulation, CTCs must first interact with endothelial cells lying in the 
luminal side of blood vessels. Although the process of tumor cell extravasation remains to 
be well defined, several similitudes to the normal extravasation process of leucocytes at 
inflammatory sites have been identified 120,150. Initial attachment of CTCs to endothelial cells 
is mediated by interaction of endothelial selectins (E-selectin) and its ligands in cancer cells 
[tetrasaccharide sialyl Lewis x (sLex) or sialyl Lewis a (sLea), MUC1 or CD44120 ,151] (Figure 
11, step 1).
Figure 10: The late steps of 
metastasis: arrest in the circulation, 
extravasation and distant metastasis 
formation. After survival in the circulation, 
cancer cells leave the circulation in a 
process called extravasation at potentially 
secondary sites. Cancer cells can be 
retained at capillary sites due to size 
restrictions, or by the specific interaction 
with adhesion molecules expressed by 
endothelial cells. After adhesion, cancer 
cells transmigrate through the endothelial 
layer (transendothelial migration or 
TEM), and after this they invade the 
endothelial basement membrane. 
Extravasated cells can then enter a state 
of dormancy or proliferate within this new 
microenvironment, were a few of them will 
give raise to metastases.
Adapted from Reymond et al 125
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After initial attachment to ECs, CTCs must establish more stable adhesions in which 
integrins are mainly involved (Figure 11, step 2). In the context of extravasation, several 
integrins on cancer cells have been implicated in their attachment to the endothelium and 
transmigration across it 152. Particularly, β1, β4 and αVβ3 integrins contributed to the strong 
adhesion between cancer and endothelial cells 120. Together with integrins, MUC1 and 
CD44 have also been implicated in this type of adhesion 153-155. Chemokine production 
by cancer cells also contributes to extravasation. For example, CCL2A (CC-chemokine 
ligand 2) produced by colon cancer cells interacts with its receptor (CCR2) on ECs to 
increase extravasation and metastasis into the lungs 156. After firm adhesion to ECs, cancer 
cells must migrate through them in a process termed transendothelial migration (TEM) 
(Figure 11, step 3). Two main forms of TEM have been described, mostly on the basis of 
work using leukocytes: Paracellular and transcellular TEM. Paracellular TEM is defined 
by the migration of cancer cells through EC junctions after their disruption by cancer cells. 
Transcellular TEM is defined as the migration of cancer cells directly through the EC body 120. So 
far, it is not clear which route is used by cancer cells in vivo, or whether the route depends 
on the vascular bed or on the cancer type.
Figure 11: Cancer cell extravasation. Cancer cells first interact with blood vessel endothelial cells 
in a transient adhesion process, which involves endothelial selectins and their counterpart receptors 
on cancer cells (1). The second step (2) consists in the establishment of firmer adhesions and is 
mediated through chemokines and cell adhesion molecules on the endothelium and integrins on 
cancer cells. The last step (3) is characterized by the extravasation of cancer cells through endothelial 
cells junctions. EC: endothelial cells; TC: tumor cells. Adapted from Gout et al 156
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2.1.5 Micrometastasis formation and target organ colonization
In order to form micrometastases, extravasated carcinoma cells must survive in the 
foreign microenvironment that they encounter in the parenchyma of distant tissues, which 
greatly differs from the one in the primary tumor. Due to this, most cancer cells will die by 
apoptosis initiated by an adverse environment 157 (Figure 10). To overcome this adverse 
scenario, two main strategies have been proposed for cancer cells to successfully 
establish a micrometastasis: adaptation of cancer cells to the new microenvironment or 
preparation of the metastatic niche prior to the arrival of cancer cells from the primary 
tumor, or both 116. One example for cancer cell adaptation involves activation of Src tyrosine 
kinase signaling, which increases the capacity of breast carcinoma cells to persist in bone 
without influencing their initial homing to this tissue. The metastatic niche preparation 
hypothesis, also termed the “premetastatic niche”, implied the release of systemic signals 
by primary tumors that induce changes in ECM proteins at distant sites 145. As mentioned 
before, the production of molecules such as lysyl oxidases (LOXs) 158, Tenascin C 148, or 
the release of vesicular structures (exosomes) 147 have been related to the formation of a 
premetastatic niche.
Successful micrometastasis formation by cancer cells does not imply further proliferation 
for the formation of large macroscopic metastases. In fact, it seems that the vast majority 
of tumor cells suffer either slow attrition over periods of weeks and months or persist 
as microcolonies in a state of apparent long-term dormancy, retaining viability in the 
absence of any net gain or loss in overall cell number 159 (Figure 12).  Factors like the 
ability of extravasated cancer cells to induce angionenesis, or their self-renewal capacity, 
have shown to be key steps for the outgrowth of micrometastases. In fact, it has been 
proposed that only a subpopulation of neoplastic cells, termed “tumor initiating cells, or 
TICs”, possess enough self-renewal ability to effectively give raise to macrometastases 160. 
EMT transcription factors such as Snail, Twist or ZEB1 (see Box 3) have been proposed 
as possible molecules facilitating the acquisition of a TIC phenotype 161. This, together 
with other factors such as microRNAs, or the coexistence with stromal cells at distant 
sites, finally enable that cancer cells complete an intricate, multistep, cell-biological 
process that culminates in the formation of macroscopic, life-threatening growths at 
distant organ sites 116.  
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2.2 Metastasis formation: a matter of number and time 
Despite the implications that the appearance of metastasis has in patient survival, the 
metastatic process, as a whole, is extraordinarily inefficient. Animal modeling suggests 
that less than 0,02% of tumor cells that are shed into the circulation can survive and form 
metastasis 159. Cancer spreading constitutes a process limited by multiple factors from its 
very early steps. Cancer cell survival at the invasive areas of primary tumors is restricted 
by the presence of an inhospitable surrounding stromal environment, together with the 
ineffective oxygen and nutrient input, due to the lack of well-established tumor vasculature. 
Data from animal models indicate that survival in the circulation, arrest at distant sites and 
extravasation seem to be the more effective processes in terms of cell survival. More than 
80% of cells intravenously implanted were found to succeed in extravasating 157. In contrast, 
once tumor cells exit the microvasculature into the parenchyma of foreign tissues, very 
low rates of cell survival are observed (<3% of intravenously implanted cells finally form 
micrometastases, and less than 0,02% form macrometastases 157) (Figure 12). Consistent 
with this experimental observation is the fact that large numbers of CTCs can be detected 
within the bloodstream of carcinoma patients, including those who develop few, if any, 
over metastases 162. Moreover, the appearance of micrometastases into the bone marrow 
of breast cancer patients, was not closely related with the development of macroscopic 
metastases, with only 50% of the patients developing tumors after 10 years 163, further 
supporting the idea of the metastatic spreading as a highly inefficient process.
Figure 12: The inefficiency of the metastatic cascade. Data from experimental models has 
revealed inefficiency of the metastasis formation process, with a rate of attrition that often exceeds 
99%. Here is depicted the approximate fraction of intravenously implanted tumor cells that have died 
after passage through the indicated steps of the invasion-metastasis cascade. Image from Valastyan 
et al 121.
In contrast to the traditional notion that metastasis is a late event in tumor progression, 
increasing evidence suggests that tumor cells can disseminate from the earliest  preneoplastic 
lesions, sometimes even before the formation of overt primary tumors 164. In small cell lung 
cancer and pancreatic cancer, metastatic disease often appears at the time of or shortly 
after the initial diagnosis, whereas many patients with breast, prostate and skin cancers 
show metastasis after a prolonged period of dormancy 165. In the case of CRC, progression 
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from adenomas to invasive carcinomas is a relatively slow process that may take years. 
However, from invasive carcinomas, tumor cell dissemination and colonization of distant 
organs (e.g. the liver or lungs) constitutes a fast event 143. It is estimated that most genetic 
alterations for CRC metastasis are acquired during progression to the invasive carcinoma 
stage, and few, if any, additional genetic events are required for the formation of distant 
metastasis 166, which may, al least in part, explain temporal dynamics of CRC progression. 
Despite the high rates of attrition that accompany certain steps of the invasion-metastasis 
cascade, overt metastasis do eventually rise in many CRC (and other carcinoma) patients, 
where they almost invariably represent the source of terminal disease. 
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Adapted from Radisky et al 167
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 3. Circulating tumor cells
Circulating Tumor Cells (CTCs) are cells that circulate in the blood of cancer patients, 
originating either from primary tumors or metastases. The presence of CTCs in patients 
with cancer was first reported in 1869 by the Australian physician Thomas Ashworth 168. 
Since their discovery, CTCs have been regarded as a very promising field of research due 
to opportunities that lie in the easy and relatively inexpensive collection of peripheral blood 
samples and thus, of tumor cells. Serial monitoring of CTCs could provide an estimate of 
circulating disease burden over time and shed light on some of the fundamental processes 
that lead to an aggressive phenotype, metastasis and resistance to current therapies. Taking 
into account that CTCs in the bloodstream are potentially coming from primary tumors, 
bone marrow and distant metastases 117,169,170, it is expectable that CTCs represent tumor 
heterogeneity as well as or better than any single biopsy 171. It is also important to note that, 
at least a subpopulation of CTCs, possibly hold all the necessary properties for the initiation of 
a metastatic tumor at a distant site, as recently reported in breast cancer 172. Altogether, these 
CTC characteristics make them a key component of the metastatic cascade where to focus 
on, due to their potential as prognosis and predictive biomarkers, but also as interesting 
targets for the development of new therapeutic strategies aiming the eradication of specific 
CTC populations responsible for metastasis formation and thus, possibly modifying the 
course of cancer disease. 
3.1 Methods for circulating tumor cell isolation 
and quantification
One main limitation for the determination of circulating tumor burden in cancer patients is 
their very rare frequency of appearance, estimated as one CTC per ≈107 white blood cells 
(WBCs) per milliliter of blood 173,174. The scarcity of CTCs and the abundance of leucocytes 
amongst they are present, demand extreme sensitive and specific CTC isolation and 
quantification methods. During the last years, an important number of technologies for CTC 
detection were developed, based on several properties that make CTCs differentiable from 
non-tumor cells also present within the blood. The expression of tumor-specific markers, 
the larger size of CTCs compared with WBCs, or some functional abilities of CTCs (e.g. 
invasiveness), have been exploited for their isolation, quantification and further molecular 
characterization (Table 8). 
Enrichment of CTCs by immunomagnetic capture has been the most successful and widely 
used approach to date. The CellSearch® platform (Janssen Diagnostics, Raritan, NJ, U.S), 
enriches CTCs using ferromagnetic beads coated with an antibody towards EpCAM, an 
adhesion molecule highly expressed in epithelial cells and absent in leucocytes. In this 
system, after enrichment, positive expression of cytokeratins 8, 18 and 19, and absence of 
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the leucocyte marker CD45, are used to identify CTCs 76,175-177 (Figure 13). However, CTC 
numbers in the circulation, especially for the analysis of non-metastatic patients, where 
CTC burden is even lower, confer a limitation to the usefulness of this system. 
To this regard, other technologies have been recently developed in order to analyze larger 
volumes of patient’s blood, allowing for the capture significant more CTCs. An interesting 
recent technology, based on the use of antibody-mediated CTC capture, is the GILUPI 
cell collector (GILUPI Nanomedizin, Germany) 178. This device consists in an anti EpCAM 
antibody-coated functionalized medical wire, which is directly placed into the antecubital 
vein of the patient for 30 min. This allows the isolation of CTCs from very large volumes of 
blood and which could increase the final CTC number. Other recent approach is the use of 
the leukapheresis (LA) technique 179. LA is a standard clinical method that is frequently used 
to isolate mononuclear cells (MNCs) from blood for various applications, including stem 
cell harvest. LA enables the extracorporeal continuous density-based cell separation of 
MNCs with a density of 1,055-1,08 g/ml from several liters of total processed blood. Taking 
into account that tumor epithelial cells fall in the optimal density for LA separation, and that 
the whole patient’s blood is processed almost three times, makes LA an optimal (although 
not easy to perform and of relative risk for the patient) technique for the recovery of large 
numbers of CTCs. 
It is also important to consider that tumors and thus probably also CTCs, are heterogeneous 
within and between patients 180,181. This, together with the fact that tumor cells may undergo 
epithelial to mesenchymal transition (EMT) during some of the steps of the metastatic 
cascade 182, implies that methodologies such as CellSearch® could be loosing specific 
tumor cell populations. CTC isolation methods based of physical properties (e.g, size, 
density, electric charges or deformability) have the advantage of being marker independent, 
consequently allowing the isolation of virtually all tumor cell types present in the blood. 
Filtration through special filters (ISET 183 and ScreenCell 184), separation of tumor cells 
based on size through centrifugal forces (Dean Flow Fractionation 185) or cell separation 
based on differential membrane capacitance (Dielectrophoretic field-flow fractionation 186) 
(Table 8) are some of the recently developed techniques for CTC isolation, independently 
of the expression of surface markers. Although not yet tested in large clinical trials, those 
methodologies are proposed as promising new strategies for better patient outcome 
prediction (due to the analysis of all CTC subtypes), but more importantly for the better 
understanding of the biology of CTCs at the molecular level.
Figure 13: Examples of circulating 
tumor cells and leucocytes isolated with 
the CellSearch® system. After EpCAM 
enrichment, CTCs are identified by their 
cytokeratin/DAPI positive and CD45 negative 
staining. Contaminating leucocytes in the 
sample are characterized by their negative 
expression for cytokeratins, and positive for 
DAPI and CD45.
57
General Introduction
Table 8. Selected technologies for CTC detection
Technology Enrichment method Detection method Notes
Antibody-based CTC capture assays
CellSearch 76,175-177 Anti-EpCAM-coated magnetic beads
ICC for CKs, CD45 and 
DAPI
FDA approved for 
advanced breast, 
prostate an colorectal 
cancer
MagSweeper 187 Anti-EpCAM-coated magnetic beads
Microscopic 
visualization
Live cells can be 
isolated
GILUPI cell 
collector 178
Functionalized EpCAM-coated 
medical wire
ICC for EpCAM, CKs 
and DAPI In vivo collection
CTC iChip 188 
Magnetic bead capture 
combined with microfluidic 
inertial focusing
ICC or RT-PCR
Positive selection by 
EpCAM or negative by 
CD45 gives a broad 
population of enriched 
cells
CTC chip 162 and 
Herringbone chip 189 
Anti-EpCAM-coated microposts 
and chip surface
ICC for CKs, CD45 and 
DAPI with/without tumor 
type specific markers.
Microfluidic microchip 
technology
Ephesia
CTC-chip 190 
Functionalized magnetic beads 
combined with microfluidics
ICC for cell surface and 
nuclear markers
Flexibility with capture 
antibody
AdnaTest 191,192 Anti MUC1/EpCAM coated magnetic beads.
Multiplex RT-PCR for a 
panel of genes (MUC1, 
HER2 or EpCAM)
Direct CTC 
quantification not 
possible due to cell 
lysis.
IsoFlux 193
Anti-EpCAM-coated magnetic 
beads combined with 
microfluidics.
ICC for CKs, CD45 and 
Hoechst.
Anti-mouse IgG-coated 
beads available for 
user-defined antibody 
capture
Physical characteristic-based assays
ISET 183 and 
Screencell 184 Filtration based on size ICC or FISH
Nonepithelial cells can 
be isolated
Dean Flow 
Fractionation 185
Size-based selection using 
centrifugal forces
ICC for CKs, EpCAM, 
CD45 and Hoechst
Nonepithelial cells can 
be isolated
Dielectrophoretic 
field-flow 
fractionation 186 
Membrane capacitance ICC Selected CTCs are viable
EPISPOT 194
CD45 depletion and short-term 
culture in  plates coated in 
antibody against MUC1, PSA or 
CK-19
IF Detection of only viable CTCs
CAM 195,196
Density gradient centrifugation 
and cells applied to CAM for 
short-term culture
ICC for cell surface 
markers
Detection of only viable 
CTCs
Other assays
ImageStream 197 Pre-enrichment by any method of choice
Flow-cytometry-
based imaging using 
multimarker IF
Cells can be imaged for 
up to 10 cell-surface or 
intracellular markers
High throughput 
fluorescent 
scanning 198
Red cell lysis and density 
gradient centrifugation
ICC of cell surface and 
nuclear markers
Nonepithelial cells can 
be isolated on a slide
DEPArray 186 Pre-enrichment by any method of choice
Fluorescence imaging 
that enables movement 
of cells within chip by 
electric field changes
Isolation of purified 
single cells for 
downstream analysis
Abbreviations:  CAM: collagen adhesion matrix, CTC: circulating tumor cell; CKs: citokeratins; DAPI: 4’,6-diamino-2-phenylindole; 
EpCAM: epithelial cell adhesion molecule; FISH: fluorescence in situ hybridization; HER2: human epidermal growth factor 
receptor 2; ICC: immunocytochemistry; MUC1: mucin 1; PSA: prostate-specific antigen; RT-PCR: real-time PCR.
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3.2 Clinical applications
3.2.1 Baseline CTC enumeration
The CellSearch® technology is currently the only FDA approved technology for CTC 
quantification in metastatic breast, colorectal and prostate cancers 76,199,200. Specifically 
for metastatic CRC (mCRC), the presence of three or more CTCs per 7,5ml of blood at 
baseline (e.g. before treatment), predicted poor patient outcome (both for PFS and OS), 
compared to patients with less than 3 CTCs, who displayed longer survival times 76,77,177. 
Similar studies in metastatic breast 175,199,201, prostate 200,202 and lung 203 cancers, have 
shown that the baseline epithelial CTC counts were prognostic for patient survival. In non-
metastatic cancers, CTCs are even more rare than in the metastatic setting. However, the 
subgroup of patients with detectable CTCs, usually comprising 10-20% of the patients, 
does have a considerable worse prognosis than those without CTCs 204,205. 
3.2.2 Circulating tumor cells as predictive markers
As previously mentioned, changes in the number of CTCs along a particular treatment 
were found to be an effective predictor of therapy response in patients suffering from 
different cancer types, and particularly in CRC. Usually enumerated using the CellSearch® 
platform, several studies were carried out in patients with mCRC, showing that reduction 
of the number of CTCs along treatment (at different times from baseline, depending on 
the study) had an impact in patient survival, with these patients showing better response 
rates and longer survival times, compared with patients with no CTC reduction or with 
an increase in number along treatment 108,109,111,112. Recently, results from a meta-analysis 
in metastatic breast cancer (mBC), show, in a cohort of more than 650 mBC patients, a 
significant correlation between the changes in the number of CTCs during treatment (after 5 
weeks from baseline) and patient prognosis (both for PFS and OS) 206. CTC analysis along 
treatment of cancer patients would ideally provide information to help clinical decisions 
regarding the possible application of second-line chemotherapies, in order to improve 
tumor response rates and avoid unnecessary therapy-derived toxicities. To this regard, 
in the SWOG0500 trial 206, 120 patients with mBC with no early CTC decrease in first-
line chemotherapy were randomized to continue the same chemotherapy line or switch 
early to the second-line. However, results showed no significant improvement in overall 
survival between both groups of patients, highlighting the clear necessity of more effective 
alternative therapies to rescue patients non-responding to first-line treatments. Despite 
the failure of treatment change based of CTC dynamics, CTC enumeration for predictive 
purposes continues to be attractive because it is less costly and relatively less invasive 
than radiologic imaging, and may provide a more rapid assessment of treatment related 
changes than radiographs, which typically require a longer period of treatment (generally 
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2-3 cycles of systemic therapy) before tumor regression becomes readily apparent. 
Ideally, CTCs will be used as a liquid biopsy to select a specific personalized therapy on the 
basis of the molecular features of a patient’s tumor.  KRAS and BRAF mutational status in 
CTCs have been assessed in mCRC patients candidates for anti-EGFR targeted therapies, 
showing discrepancies with gene mutations found in primary tumor tissue 207, probably 
due to primary tumor heterogeneity.  In non small-cell lung cancer (NSCLC), several 
studies have demonstrated the utility of the analysis of EGFR mutations or EML4-ALK 
rearrangements in CTCs, for the prediction of targeted therapies effectiveness, or for the 
identification of resistance biomarkers 208-210. However, determination of specific mutations 
in CTCs remains challenging, due to the low number of CTCs, the lack of amplification of 
genes of interest or to the presence of an elevated number of leucocytes in the sample 
even after CTC enrichment. 
3.2.3 Global molecular profiling of CTCs
Large scale molecular profiling of CTCs is even more challenging than the mere enumeration 
or the evaluation of the molecular status of single genes by different methodologies. 
Gene-expression profiling of CTCs provides a very interesting insight into their biology and 
heterogeneity, allowing the identification of molecular CTC-markers related with different 
steps of the metastatic cascade, at the same time that identifies potential therapeutic 
CTC-based targets 211-213. However, RNA degradation and the presence of an elevated 
amount of biological “noise” in CTC enriched samples, remain significant hurdles for 
effective CTC transcriptomic analysis.  Transcriptional profiling of single CTCs, isolated 
by micromanipulation, provides a smart solution for the understanding of molecular CTC 
characteristics, avoiding the negative influence of the presence of contaminating leucocytes 
in the sample 214,215. Although these techniques remain in their infancy, the contribution that 
single-cell profiling of CTCs could make to our understanding of cancer heterogeneity, 
disease evolution, and tumor biology is clearly evident. 
Global genetic alterations can be also assessed in CTCs at a genomic level, which provides 
essential information about how representative are CTCs from the total heterogeneity 
present in the primary tumor or in metastatic tissues. For example, in CRC, array-
comparative genome hybridization (CGH) and next generation sequencing (NGS) of a panel 
of CRC-associated genes of isolated CTCs, compared with matched primary tumors and 
metastases, showed the presence of CTC exclusive mutations or genetic aberrations, not 
detected in tumor tissues. Interestingly, most of CTC-specific alterations were subsequently 
detected in primary tumors at a subclonal level after additional sequencing, indicating that 
CTCs could better provide a global overview of tumor genomics and have the potential of 
be more informative than analysis of single biopsy samples 216.
60
Chapter I
4. Integrin signaling and Talin
Regulating adhesion and de-adhesion between cells and their surrounding extracellular 
matrix (ECM) is critical for cell migration, for example during embryonic development, 
immune responses, cardiovascular function, angiogenesis and tumor invasion and 
metastasis, as well as for other cell features like survival and proliferation 217,218. In the last 
part of this thesis we described Talin1, a key component for the establishment of cell-ECM 
interactions at focal adhesion (FA) sites, as a relevant molecule for CTC extravasation from 
blood and subsequent metastasis formation. 
FAs are large multiprotein complexes that assemble around the integrin family of cell 
adhesion molecules (heterodimers of noncovalently associated α and β subunits) that 
are typically linked to the actin cytoskeleton 219. Talin 220,221, together with filamin 222 and 
α-actinin 223,224, are known to be the key players in this linkage, which can bind directly and 
simultaneously to both actin and integrin cytoplasmic tails. 
The effects of Talin on integrin function are broad. It transduces signals across integrins in 
both the inside-out and outside-in directions and it also influences the organization of the actin 
network and the composition of focal adhesions 225-227. Talin was discovered in 1983 by the 
group of Barridge and coworkers, as a protein highly enriched at cell adhesion sites 228,229. 
Two different isoforms of the Talin gene (Tln) have been described in mammals: Tln1 and 
Tln2. Both isoforms share 74% identity. However, their expression pattern is different, 
with Tln1 gene expressed almost ubiquitously and Tln2 expressed mainly in heart and 
brain 230. Moreover, and despite the high identity rate between both isoforms, they do not 
compensate each other. When Tln1 is inactivated, Tln2 levels do not increase and existing 
levels do not compensate for Tln1, and vice versa 231-233. Moreover, Tln1 knockout mice are 
embryonically lethal, due to defects during the process of gastrulation, while Tln2 mice are 
viable and fertile 233.
Figure 14: Domain structure and binding partners of Talin. Talin comprises a globular N-terminal 
head domain, and a flexible rod domain. Binding sites for β-integrins, Actin, Vinculin, FAK, laylin and 
phosphatidylinositol (4)-phosphate 5-kinase, as well as cleavage site for Calpain 2 are represented. 
Adapted from Critchley et al 233.
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The human Talin is a 270KDa protein composed of 2541 amino acids (aa) and consists of an 
N-terminal head (433aa) (Talin-H) followed by a much larger rod domain (Talin-R) (Figure 
14). Talin-H contains four subdomains (F0, F1, F2 and F3) with F1-F3 being homologous 
to a typical FERM domain (F for 4.1 band protein, E for Ezrin, R for Radixin and M for 
Moesin), which is implicated in the localization of proteins to the plasma membrane 234, 
as it has binding sites for the cytoplasmic domains β-integrins and laylin (a hyaluronan 
receptor) as well as for filamentous actin (f-actin). The head domain also binds to two 
signaling molecules that regulate the dynamics of FAs, namely PIPK1γ90 (a splice variant 
of phosphatidylinositol (4)-phosphate 5-kinase type Iγ) and focal adhesion kinase (FAK), 
although it is not clear whether binding of FAK is direct 219. Talin-R consists of a series 
of helical bundles which contain multiple protein binding sites for Vinculin 235, RIAM 236, 
integrin 237, and a dimerization sequence at the C-terminus 238 (Figure 14). 
In resting state cells, Talin distribution is random and diffuse and is autoinhibited from 
binding to integrins and membrane. Talin-R plays a major role to structurally restrain the 
Talin-H binding to the plasma membrane and integrins 227. Upon agonist stimulation, Talin 
is rapidly localized to the plasma membrane 239. Protein Kinase C alpha (PKCα), Rap1A, 
Rap1 effector RIAM, and phosphatidylinositol 4,5 biphosphate (PIP2) have been shown 
to play important roles in the Talin membrane localization and activation of its integrin 
binding function 227,240,241 (Figure 15). Calpain 2-mediated cleavage of Talin also facilitate 
the binding of Talin1 to integrins, but cleavage appears not to be required for integrin 
activation in cells 242. 
Figure 15: Mechanism of Talin activation. In resting cells, Talin is in a autoinhibitory folded 
conformation, with vinculin-binding sites dormant (in green). Upon activation, mediated by 
RIAM, Rap1, PKC or PIP2, Talin conformation changes into its unfolded version, and Vinculin 
binding sites become activated (in red), as well as F3 head domains, promoting Talin binding to 
β-integrins cytoplasmic tails. The secondary integrin binding sites are represented in orange. 
Image from Das et al 241.
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Once Talin is activated, it is recruited to focal adhesion complexes to functionally interact 
with integrin cytoplasmic tails. Since Talin contains two β integrin binding sites, one within 
the FERM and the other within the rod domain, Talin homodimers have up to four integrin-
binding sites, thus providing a biochemical base to Talin’s ability to act as an integrin 
crosslinker, promoting clustering of integrins at specific focal adhesion sites 243.
Binding of Talin to integrin cytoplasmic tails has been widely studied, finding higher affinity rates 
to β1 and β3 integrin subunits 219,244. Following the interaction of Talin1 with the β-integrin tail, 
conformational changes are propagated across the membrane to the extracellular domains 
of integrins, increasing their affinity for ligands. After binding of individual integrins to their 
ECM ligands, a Talin-mediated connection is formed between the ECM and the cytoskeleton, 
giving raise to the formation of nascent adhesions. Forces transmitted through these immature 
adhesions contribute to the reinforcement of the ECM-cytoskeleton link and to the recruitment 
of additional cytoskeletal and signaling proteins 245. As adhesions mature, multiprotein 
complexes assemble at the cytoplasmic face of clustered, ligand-bound integrins, forming 
mature focal adhesions and finally transmitting signals into the cell, regulating processes 
such as cell spreading, adhesion or migration 227,246. Proteins recruited to focal adhesion 
complexes include focal adhesion kinase (FAK), Src-family kinases, integrin-linked kinase 
(ILK), paxillin or vinculin, among others, and together orchestrate the whole array of cellular 
functions regulated through the interaction of cell-ECM at focal adhesion sites 246.
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The main objectives of this thesis have been delineated in order to cover some of the 
major current limitations in the field of CTC research, with the final goal of improving 
patient clinical management. By focusing on mCRC patients, this thesis comprises four 
principal objectives: the improvement of CTC detection methods sensitivity, the molecular 
characterization of CTCs for the deepening in their functional biology, the optimization of 
new prognostic and predictive CTC-related biomarkers and finally, the discovery of CTC-
related molecules critical for the efficiency of metastatic dissemination. 
1. The development of an improved method for CTC isolation and quantification 
from patients with mCRC.
a. The design of an improved qPCR-based CTC detection procedure, in 
order to maximize detection rates. 
b. The search for potential candidate genes for CTC detection, based on their 
expression pattern in epithelial and intestinal tissues. Their expression 
analysis in CTC-enriched samples from mCRC patients, using healthy 
donor’s blood as a background indicator. 
c. The development of a mathematical model for the combination of selected 
CTC-markers, and its validation as a prognostic factor for the prediction of 
mCRC patient’s survival. 
2. The molecular characterization of CTCs in mCRC patients, in terms of their 
gene expression profile.
a. The optimization of a methodology to explore the genetic characteristics of 
CTCs from very low cellularity samples, based on the linear amplification of 
the genetic material obtained using the technique proposed on objective 1, 
and its hybridization onto gene expression microarrays.
b. The determination of the specific gene expression profile of CTC-enriched 
samples from mCRC patients, using negative control samples from healthy 
volunteers as background indicators. 
c. A bioinformatic analysis on the main biological pathways and processes 
underlying CTC gene-expression profile.
d. The validation of microarray data by testing the expression of a set of 
selected CTC-specific genes by qPCR in an independent cohort, and in 
primary and metastatic tumor tissues.
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3. The evaluation of a panel of CTC markers as a prognostic and predictive tool 
for the analysis of therapy response in mCRC patients.
a. The selection of CTC-markers from objectives 1 and 2 for the improved 
CTC quantification using the general methodology described in objective 1.
b. The gene expression assessment of a set of EMT markers in a group 
of CTC-isolated samples from mCRC patients, and its comparison with 
samples from healthy volunteers. The selection of CTC-related EMT 
markers differentially expressed between patients and controls.
c. The evaluation of the prognostic value of the selected CTC-marker panel 
for the prediction of patient survival at baseline (before treatment).
d. The classification of mCRC patients in therapy responders o non-
responders based on the variations of CTC-markers along treatment and 
the analysis of their predictive value.
e. The direct comparison of CTC-markers and conventional imaging 
techniques for the early assessment of therapy response. 
4. The characterization of the role of Talin1 in the process of metastatic 
dissemination mediated by CTCs, and the analysis of Talin1 as a new 
potential therapeutic target in mCRC.
a. The search for candidate CTC-genes from objective 2 and the validation of 
Talin1 as a molecule expressed in CTCs from mCRC patients.
b. The study of the effect of Talin1 depletion in HCT116 and CT26 colorectal 
cancer cell lines on in vitro assays mimicking the process of CTC 
extravasation from the bloodstream, by interaction with endothelial cells 
and subsequent basement membrane invasion.
c. A study of the importance of Talin1 for metastasis formation from 
CTCs, modeled using HCT116 cell line, in an in vivo mouse model for 
hematogenous cancer dissemination. 
d. The assessment of Talin1 expression levels in CTCs from mCRC patients 
as a prognostic and predictive biomarker, as well as its expression pattern 
in primary colorectal carcinomas and metastatic tissues.


Chapter II
A logistic model for the detection 
of circulating tumor cells in human 
metastatic colorectal cancer
Jorge Barbazán, María Vieito, Alicia Abalo, Lorena Alonso-Alconada, Laura Muinelo-
Romay, Marta Alonso-Nocelo, Luís León, Sonia Candamio, Elena Gallardo, Urbano 
Anido, Andreas Doll , María de los Ángeles Casares, Antonio Gómez-Tato, Miguel Abal 
& Rafael López-López 
J Cell Mol Med, Vol 16, No 12, 2012, pp 2342-2349
http://onlinelibrary.wiley.com/doi/10.1111/j.1582-4934.2012.01544.x/abstract;jsessionid=483295FD67D56D715307464294B0A1FA.f02t01

Chapter III
Molecular characterization of 
circulating tumor cells in human 
metastatic colorectal cancer
Jorge Barbazán, Lorena Alonso-Alconada, Laura Muinelo-Romay, María Vieito, 
Alicia Abalo, Marta Alonso-Nocelo, Sonia Candamio, Elena Gallardo, Beatriz 
Fernández, Ihab Abdulkader, María de los Ángeles Casares, Antonio Gómez-Tato, 
Rafael López-López & Miguel Abal
PlosOne, July 2012, Volume 7, Issue 7, e40476
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0040476

Chapter IV
A multimarker panel for 
circulating tumor cells detection 
predicts patient outcome and 
therapy response in metastatic 
colorectal cancer
Jorge Barbazán, Laura Muinelo-Romay, María Vieito, Sonia Candamio, Antonio 
Díaz-López, Amparo Cano, María de los Ángeles Casares, Antonio Gómez-Tato, 
Rafael López-López & Miguel Abal
Int J Cancer, April 2014, doi.1002/ijc.28910. In press
http://onlinelibrary.wiley.com/doi/10.1002/ijc.28910/full

Chapter V
Talin1 enhances colorectal cancer 
dissemination through circulating 
tumor cells by promoting cancer 
cell extravasation and invasion
Jorge Barbazán, Nadia Elkhatib, Sara Geraldo, Lorena Alonso-Alconada, Vasily 
Gurchenkov, Alexandros Glentis, Beatriz Fernández, Tomás García-Caballero, 
Rafael López-López, Danijela Vignjevic & Miguel Abal
Submitted

79
Talin1 enhances colorectal cancer 
dissemination through circulating 
tumor cells by promoting cancer cell 
extravasation and invasion
Jorge Barbazán1, Nadia ElKhatib2, Sara Geraldo2, Lorena Alonso-Alconada1, 
Vasily Gurchenkov2, Alexandros Glentis2, Beatriz Fernández3, Tomás García-
Caballero3, Rafael López-López1, Danijela Vignjevic2 and Miguel Abal1,* 
1 Translational Laboratory, Medical Oncology Department. Complexo Hospitalario Universitario de Santiago de Compostela
  SERGAS; Trav Choupana s/n 15706. Santiago de Compostela, Spain.
2 Institut Curie, UMR144, CNRS, Paris 75005, France.
3 Department of Pathology, Complexo Hospitalario Universitario de Santiago de Compostela/SERGAS, Santiago de Compostela, Spain.
Key words: Circulating Tumor Cells, Talin1, Extravasation, Metastasis, Endothelial cells, Basement membrane invasion
Running title: Talin1 promotes CTC dissemination in colorectal cancer
* Corresponding author: Miguel Abal, Translational Medical Oncology Laboratory, Medical Oncology Department, Complexo 
Hospitalario Universitario de Santiago de Compostela/SERGAS; Trav Choupana s/n 15706, Santiago de Compostela, Spain.
Tel: +34 981955073
Fax: +34 981950535
E-mail: miguel.abal.posada@sergas.es
History: Submitted
The appearance of cancer metastasis constitutes the main factor that determines patient outcome, 
causing a dramatic drop in survival rates. During tumor dissemination, circulating tumor cells (CTCs) 
must interact with blood-vessels endothelial cells to effectively extravasate from the circulation 
and possibly give raise to the formation of distant metastasis. We have previously reported a gene 
expression signature of CTCs in metastatic colorectal cancer (mCRC) that highlighted the importance 
of cell adhesion and migration abilities for CTC biology. In this work, among these genes described 
as CTC-specific, we have identified Talin1 as a potential molecule driving CTC extravasation. Talin1 
depletion in CRC cell lines suppressed their ability to adhere and endothelial monolayer and further 
transendothelial migration, partially due to their inability to establish focal contacts with fibronectin 
fibers at the surface of endothelial cells, a novel cell-cell interaction mechanism described here. Talin1 
also influenced later extravasation steps by regulating basement membrane invasion. These in in vitro 
findings were further confirmed in an in vivo model for cancer hematogenous dissemination. Finally, 
Talin1 expression in CTCs from mCRC patients was found to correlate with patient prognosis as well as 
with therapy response. Altogether, these findings suggest: i) a principal role for Talin1 in the process 
of CTC escape from the circulation and subsequent implantation prior to metastasis establishment 
and ii) a potential value for Talin1 as a therapeutic target against cancer dissemination and as a 
prognosis and predictive tool, key points to improve patient’s management at the clinical setting.
Introduction
Colorectal Cancer (CRC) constitutes the third 
cancer type worldwide in terms of incidence 2. The 
appearance of metastasis, a stepwise sequence 
of events by which primary tumors spread to 
distant sites, represents the main cause for 
CRC related deaths 306. To effectively establish 
secondary tumors, cancer cells must overcome 
a large number of physical and biological barriers 
before colonizing distant sites. After breaching of 
the basement membrane (BM) at the primary 
site, intravasation into pre-existing and newly 
formed blood and lymph vessels, and survival in 
the circulation, tumor cells must extravasate from 
the bloodstream at the target organ before its 
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colonization 138,143. Despite the low efficiency of 
the metastasis process (only 0,01% of the tumor 
cells reaching the circulation might develop into 
distant tumors 157), metastatic disease continue 
to be the main challenge in oncology.
Circulating Tumor Cells (CTCs), tumor cells 
that escape the primary tumor and reach the 
bloodstream, are considered to be one of the 
main responsible for cancer dissemination 143,307. 
During the last years, several methodologies 
have been developed for the effective isolation, 
quantification and characterization of CTCs from 
patients with different malignancies 308, widely 
evidencing their prognostic value 83. Moreover, it 
has been recently shown that CTCs can initiate 
metastasis in a xenograft model 172, reinforcing 
their role as metastatic cells and positioning 
CTCs as interesting targets for the treatment of 
disseminated disease. 
Recently, our group reported a global gene 
expression profile of CTCs coming from 
metastatic CRC (mCRC) patients, in which we 
described a set of CTC-specific genes that could 
serve as detection and prognosis markers, but 
also as potential therapeutic targets due to their 
expression in CTCs 213. Among them, we found 
Talin1, a protein encoded by the TLN1 gene, which 
belongs to the integrin-signaling pathway. Together 
with a large number of others, Talin1 is involved 
in the formation of focal adhesions (FAs) at cell-
extracellular matrix (ECM) contact sites. Talin1 links 
the cytoplasmic domains of β1 and β3-Integrins 
to actin filaments in the cytoplasm 219,309, playing 
a key role in the process of integrin inside-out 
activation, but also as a transducer molecule 
for outside-in signaling upon integrin activation 
and interaction with the ECM 227,310. Regarding 
the role of Talin1 in cancer, it has been recently 
shown that Talin1 expression was related with 
cancer progression to metastasis in prostate 
and in oral squamous cell carcinomas 140,311, by 
promoting increased tumor invasiveness and 
anoikis resistance.
Cancer hematogenous dissemination through 
CTCs requires the attachment of cancer cells 
in the bloodstream to the endothelial layer of 
blood vessels, as a first step in extravasation 312, 
process in which several adhesion molecules, 
including integrins, are involved 312,313. Elevated 
Talin1 expression in CTCs from mCRC patients, 
lead us to hypothesize a role for this molecule 
in the process of CTCs escape from the 
circulation and thus, for metastasis formation. 
In this work we evaluated how Talin1 is involved 
in different steps of tumor cell extravasation, 
including attachment to endothelial monolayers, 
transendothelial migration (TEM) and BM 
invasion. We also demonstrate that Talin1 
influences metastasis formation in an in vivo 
model for cancer dissemination. Moreover, 
Talin1 expression levels in CTCs from mCRC 
patients were found to be an effective marker for 
prognosis and therapy response effectiveness. 
Altogether, our results suggest Talin1 both as 
an interesting marker for patient outcome and 
as a potential therapeutic target against cancer 
dissemination through CTCs.
Materials and methods
Cell culture
Human adenocarcinoma HCT116 and mouse 
carcinoma CT26 colon cancer cell lines were 
obtained from American Type Culture Collection 
(ATCC) and cultured in DMEM medium (Life 
Technologies) supplemented with 10% Fetal 
Bovine Serum (FBS) (Life Technologies) and 
1% penicillin/streptomycin (Life Technologies). 
Human Umbilical Vein Endothelial Cells 
(HUVEC) were obtained from Life Technologies 
and cultured in endothelial basal medium EBM-
2 (Lonza). For HUVECs, culture vessels were 
pretreated with 0,2% gelatin diluted in PBS for 
30min at 37ºC. Human Embryonic Kidney 293 
(HEK293) cells were purchased from ATCC and 
cultured in DMEM medium supplemented with 
10% FBS and 1% penicillin/streptomycin. 
Plasmids, shRNA, antibodies and proteins
EGFP tagged Paxillin was kindly provided by 
D Vignjevic (Institut Curie, Paris). Luciferase 
reporter pLenti CMV V5-LUC Blast (w567-1) 
and lentiviral packaging and envelope vectors 
(psPAX2 and pmD2.G, respectively) were 
purchased from Addgene. Lentiviral transduction 
particles bearing ShRNA against Talin1 (human: 
5’-CCGGCCCAGAGTATTAACGCTCCAACT 
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CGAGTTGGAGCGTTAATACTCTGGGTTTT 
TG-3’ and 5’-CCGGGCCTCAGATAATCTGGTG 
AAACTCGAGTTTCACCAGATTATCTGAGG 
CTTTTT-3’,                     mouse: 
5’-CCGGTGGTGAAGACGATGCAATTTGC 
TCGAGCAAATTGCATCGTCTTCACCATTT 
TTG-3’ and 5’-CCGGCGCTCCAAGAGTATTA 
TTAATCTCGAGATTAATAATACTCTTGGAG 
CGTTTTTG-3’ and Non 
Target Control (NTC) shRNA 
(5’-CCGGCAACAAGATGAAGAGCACCAA 
CTCGAGTTGGTGCTCTTCATCTTGTTGTT 
TTT-3’) that targets not known mammalian genes, 
were purchased from Sigma Aldrich (MISSION 
Transduction Particles). All experiments were 
performed using two independent ShRNAs for 
each cell line, obtaining similar results for both. 
Only one is shown in the results section for 
simplification. 
Mouse anti-α-Tubulin (Clone DM 1A) and rabbit 
anti-Fibronectin were from Sigma-Aldrich. 
Goat anti-Talin (C20) was from Santa Cruz 
Biotechnology. Mouse anti-Vinculin was obtained 
from Dr Vignjevic (Institut Curie, Paris). Labelled-
phalloidin, DAPI and all secondary antibodies 
were purchased from Molecular Probes.  Human 
fibronectin was purchased from Life Technologies 
and used at 20μg/ml in PBS for surface coating 
(1h at room temperature or overnight at 4ºC).
Lentiviral infections
For Talin1 knockdown, 2x104 HCT116 or CT26 
cells were seeded on a 24-well plate and 
incubated 24 hours at 37ºC. Next day, culture 
medium was replaced and Hexadimethrine 
Bromide (HDMB) (Sigma Aldrich) was added at a 
final concentration of 8μg/mL. Lentiviral infection 
was carried out following manufacturer’s 
instructions using a multiplicity of infection (MOI) 
of 10 (previously optimized using MISSION 
TurboGFP Control Transduction Particles (Sigma 
Aldrich)). Puromycin (Life Technologies) was 
used as selection antibiotic at a concentration of 
1μg/mL (for HCT116) and 6μg/mL (for CT26). 
For the generation of luciferase expressing cells, 
viral particles were generated in HEK293 cells 
by co-transfection of packaging and envelope 
vectors (psPAX2 and pMD2.G, respectively) 
together with pLenti CMV V5-LUC Blast (w567-
1) using Lipofectamine 2000 (Life Technologies), 
according manufacturer’s instructions. 48 hours 
after transfection, culture medium containing 
lentiviral particles was collected, filtered and 
added to HCT116 and CT26 cells (shControl 
and shTalin1) for 24 hours. Hexadimethrine 
Bromide (HDMB) (Sigma Aldrich) was added 
at a final concentration of 8μg/mL. Cell lines 
stably expressing luciferase reporter gene were 
selected and maintained with Blasticidine HCL 
(Life Technologies) at 10μg/mL.
Western blot
Cells were washed with PBS, lysed in lysis 
buffer (1% triton, 50mM Tris pH7.5,1mM EDTA, 
150mM NaCl and protease inhibitors cocktail 
(Sigma Aldrich). Protein was quantified using the 
Bicinchoninic Acid assay (BCA) (Sigma Aldrich) 
and boiled in 2x Laemmli buffer. The samples were 
separated by SDS-PAGE on 10% gels, transferred 
to nitrocellulose membranes, and blocked in 5% 
non-fat dried milk for 60 min. The membranes 
were incubated with primary antibodies overnight 
at 4ºC followed by incubation with peroxidase-
conjugated secondary antibodies for 1h at RT. 
Immunoreactive bands were detected using an 
ECL kit (Thermo Scientific).
Real time quantitative gene expression
To check Talin1 knockdown at mRNA level, 
cancer cells were washed once with PBS and 
RNA was extracted with the High Pure RNA 
isolation kit (Roche) following manufacturer’s 
instructions. cDNA was synthesized (MuLV 
reverse transcriptase, Life Technologies), 
and gene expression was evaluated using 
hydrolysis probes (Life Technologies). Data 
was represented as fold change relative to the 
expression in the non-target controls. GAPDH 
was used as loading control.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde in PBS 
for 20 min, followed by permeabilization with 
extraction buffer for 30 secs [0.5% Triton X-100 
and 4% PEG (MW 40 000) in cytoskeleton PEM 
buffer (100 mM Pipes, pH 6.9, 1 mM MgCl2, 
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and 1 mM EGTA)] containing 2μM phalloidin. 
After permeabilization, cells were briefly washed 
twice with PEM buffer and once with PBS. 
Primary antibodies were diluted in PBS and 
incubated at 1:100 dilution (except for mouse 
anti-vinculin, 1:2), for 1h at room temperature in 
a humid chamber. Secondary antibodies were 
diluted 1:200 in PBS and incubated together with 
labelled phalloidin (1:200) and DAPI (1:1000) for 
1h at room temperature in the dark. Cells were 
then washed with PBS and mounted onto glass 
slides with Prolong Gold (Life Technologies).
Quantification of FAs size and number
CT26 and HCT116 cells (Control and Talin1 
Knockdown) were seeded onto fibronectin-
coated coverslips. After 12-16h (for CT26) or 
48h (for HCT116) cells were fixed and stained 
for Vinculin, Talin, Phalloidin and DAPI. Cells 
were imaged with a 100x objective of a wide-field 
microscope (DM6000 B/M; Leica) equipped with 
a CCD camera (CoolSNAP HQ;Photometrics). 
The lengths of FAs were measured using 
the MetaMorph Imaging software. 10 cells 
were quantified for each different cell line and 
condition.
Quantification of FAs dynamics
CT26 (shControl and shTalin1) cells were transfected 
with EGFP-tagged Paxillin using a Nucleofector 
(Lonza) according to the manufacturer’s instructions 
and seeded onto fibronectin-coated glass dishes. 
Turnover of FAs was analyzed 24h later using 
63x NA 1.4 objective of an inverted microscope 
(TE2000; Nikon) equipped with a spinning dish 
head (CSU22; Yokogawa) and a charge coupled 
device camera (CoolSNAP HQ2; Photometrics). 
Images were acquired every 2 minutes for during 
3-4 hours. FA turnover was defined as elapsed time 
between the first and the last frames in which FA 
was observed. At least 150 FAs were quantified for 
each condition in a minimum of 10 different cells. 
Lamellipodia lifetime was defined as the elapsed 
time between the first frame where one single 
lamellipodia protrusion started to form, until the 
frame where it completely retracted. A minimum 
of 10 different cells was analyzed. Mann-Whitney 
test was used to evaluate significant differences 
between conditions. 
Cell proliferation assay
For the analysis of cell proliferation dynamics, 
104 cancer cells were seeded per well on 96-
well culture plates and incubated at 37ºC for 
24, 48 and 72h. After incubation, the number of 
viable cells was determined by using AlamarBlue 
(Life Technologies) following manufacturer’s 
recommendations. 
Adhesion assays
For evaluation of tumor cell adhesion to 
HUVECs, 3x104 endothelial cells were seeded 
in gelatin-coated 96-plate wells and incubated 
overnight for cell monolayer formation. Cancer 
cells were stained with Calcein AM (Life 
Technologies) and plated at a concentration of 
2,5x105 cells/well over HUVEC monolayers in 
triplicates. Basal fluorescence emission was 
measured immediately after cell seeding in a 
microplate luminometer (LumiStar Optima, BMG 
LabTech) to evaluate possible differences in cell 
number. Cells were then incubated at 37ºC for 
the specified time. After incubation, wells were 
washed three times to remove non-adherent 
cells, and fluorescence intensity was measured. 
Adhesion was represented as the percentage of 
adherent cells per condition, normalized to the 
initial cell number per well. All experiments were 
run at least three independent times.Adhesion of 
tumor cells to different ECMs was tested using 
the ECM Cell Adhesion Array plates (Millipore), 
following the previous Calcein AM labeling 
protocol. 
Flow-adhesion assays
For the evaluation of tumor cell adhesiveness 
under flow conditions, we used a setup composed 
by a culture chamber (PocMini-2, PeCon GmbH) 
connected to a syringe pump (NE-1000, New 
Era Pump Systems Inc) The culture chamber 
was placed on a thermostated platform to 
maintain the temperature at 37ºC during the 
experiment. The whole setup was placed in an 
inverted microscope (Zeiss Axio Vert A1) to allow 
cell visualization. Tumor cells were stained with 
Calcein AM and resuspended at a concentration 
of 105 cells/mL in complete growth medium. Cells 
were then pumped through the culture chamber 
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at 500μl/min during 1 hour, followed by a 10min 
wash with complete medium. After this time, 
the bottom glass from the culture chamber was 
removed and gently washed with culture medium 
to eliminate non-attached cells. Tumor cells 
attached to the glass surface, were trypsinized, 
centrifuged and resuspended in 100μl of PBS. 
Attached cells were indirectly quantified by 
fluorescence emission measurement in a 
luminometer. To evaluate cell adhesiveness 
under flow conditions, the bottom glass of 
the culture chamber was either coated with 
fibronectin, or seeded with 5x105 HUVECs in 
EBM-2 medium and incubated at 37ºC overnight 
for monolayer formation. All experiments were 
performed in three independent runs. 
2D and transwell migration assays
For the evaluation of cell migration ability in two-
dimensional surfaces, CT26 cells (ShControl and 
shTalin1) were seeded onto fibronectin-coated 
glass bottom dishes. Cells were incubated 15 
minutes at 37ºC for initial cell attachment, and 
then migration was visualized in clear field under 
an inverted videomicroscope (Nikon Eclipse Ti) 
using a 10x objective. Images were acquired 
every 3 minutes for 8 hours and 10 random fields 
were imaged for each condition. Migration speed 
and path length was quantified using the manual 
tracking plugin implemented on Fiji (ImageJ) in 
50-100 cells per condition. Experiments were 
performed three independent times. 
For transwell migration assays, 105 CT26/HCT116 
cells (ShControl and shTalin1) were seeded 
on the upper chamber of 24-well hanging cell 
culture inserts (8,0 µm pore size polycarbonate 
membrane; Millicell, Millipore) in 100 µl of DMEM 
medium containing 5% FBS. The lower chamber 
was filled with DMEM supplemented with 20% 
FBS to create an FBS chemotactic gradient. 
Cells were incubated for 24h (CT26) or 72h 
(HCT116) at 37ºC. Cells that migrated through 
the membrane were trypsinized, collected and 
stained with Calcein AM (5 µM) according to 
manufacturer’s recommendations. After staining, 
cells were centrifuged, resuspended in 100 µl of 
PBS and fluorescence intensity was quantified 
using a luminometer. Three independent assays 
were run for each experimental condition. 
Results were represented as the relative number 
of shTalin1 migrating cells compared to control 
cells, defined as 100%, for each cell line.
Transendothelial (TEM) migration assay
The effect of Talin1 knockdown on migration 
through an endothelial monolayer was evaluated 
using transendothelial migration assays. 105 
HUVECs were seeded on the upper chamber 
of a gelatin-coated 24-well hanging cell culture 
insert (Millicell, Millipore) in EBM-2 complete 
medium, and incubated 4-6h at 37ºC to form a 
monolayer. Monolayer integrity was assessed 
in a control insert by addition of high-molecular-
weight FITC-dextran (Sigma Aldrich) to the upper 
chamber (1mg/mL). 600 µl of EBM-2 medium 
were added to the lower chamber. Every 30 min, 
50 µl samples were collected from the lower 
chamber and diluted to 1ml with PBS. 100 µl of 
diluted sample were transferred to a 96-well black 
plate and fluorescent content was quantified at 
492/520 nm absorption/emission wavelengths. 
No fluorescence intensity is detected in the lower 
chamber once the HUVEC monolayer reaches 
confluency. 
5x105 CT26 cells (control and shTalin1) were 
stained with Calcein AM (Life Technologies) as 
previously described, and added to the upper 
chamber of the cell culture insert once the 
HUVEC monolayer was established, in 10%FBS 
DMEM medium. 20%FBS DMEM medium 
was added to the lower chamber to create a 
chemotactic gradient. Cells were allowed to 
migrate through endothelial cells for 24h at 37ºC. 
Transmigrated cells were trypsinized, collected, 
centrifuged, resuspended in 100 µl of PBS 
and fluorescence emission was measured in a 
luminometer. At least three independent assays 
were run for each experimental condition. Results 
were represented as the relative shTalin1 CT26 
transmigrated cells compared to control CT26 
cells, defined as 100%.
HUVEC monolayer integrity assay
Disruption of HUVE cells monolayer integrity 
by cancer cells was analyzed using the 
XCELLigence system (Roche Applied Sciences) 
as previously described 327 This method enables 
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real-time monitoring of cellular events by using 
impedance measurements across interdigitated 
microelectrodes integrated on the bottom 
of tissue culture microtiter plates (E-plates). 
Impedance changes occur if cells attach to 
E-plates or change their size, shape and 
number. Briefly, 2,5x104 HUVECs were seeded 
on gelatin-coated E-plates and incubated 20-24 
hours for monolayer establishment. Impedance 
readings were performed every 10 minutes and 
monolayer formation was evidenced by a cell 
index flattening. After this time, 2x104 HCT116 
or CT26 cells (ShControl and ShTalin1) were 
added on top of the HUVE cells and impedance 
was monitored again for 1-4 hours. Invasion of 
cancer cells was measured by their ability to 
trigger endothelial cells retraction, which results 
in a cell index drop. Results were normalized to 
the time of addition of tumor cells, and invasion 
was quantified as the slope variation along the 
analysis time for each condition. Experiments 
were performed in duplicates and repeated three 
independent times.
Tumor cell-HUVEC interaction assay
For the evaluation of fibronectin production by 
HUVECs, 105 endothelial cells were seeded 
on gelatin-coated 12mm glass coverslips 
and incubated overnight at 37ºC. Cells were 
then fixated with 4% PFA for 20min at room 
temperature, stained for fibronectin, phalloidin 
and DAPI, and visualized on a Leica SP5 
confocal microscope. Images analysis and three-
dimensional reconstructions were performed 
with Fiji (ImageJ). For analysis of cancer cell-
endothelial cell interaction, 4x105 CT26 control 
and shTalin1 cells were seeded on 12-well 
plates and transfected to transiently express 
EGFP-Paxillin using Lipofectamine LTX (Life 
Technologies) according to manufacturer’s 
protocol. 105 HUVECs were seeded on a gelatin-
coated 12mm glass coverslip and incubated 
overnight to form a monolayer. After 24 hours 
of transfection, cancer cells were trypsinized 
and seeded on top of the HUVEC monolayer 
in 10%FBS DMEM medium. Cocultures were 
incubated for 2 hours at 37ºC to allow tumor cell-
HUVEC contact establishment. Cells were then 
fixated with 4% Paraformaldehyde (PFA) (Sigma 
Aldrich) for 20min at room temperature, washed 
with PBS and stained for fibronectin, phalloidin 
and DAPI. Cell interactions were visualized with 
a 100x objective of a wide-field microscope 
(DM6000 B/M; Leica) equipped with a CCD 
camera (CoolSNAP HQ;Photometrics). 
Native basement membrane migration/
invasion assay
The influence of Talin1 on migration/invasion 
on a physiologic system was evaluated as 
previously described by Schumacher et al 314. 
The peritoneal basement membrane (BM) was 
isolated from BALBc mice, and mounted on 
6,5mm diameter Transwell (BD Biosciences) 
from which the polycarbonate membrane was 
cut out, using tissue adhesive (Vetbound, 3M). 
Mesothelial cells were eliminated by treating 
the membrane with ammonium hydroxide (1M) 
(Sigma Aldrich) for 1h at room temperature. After 
PBS washing, 105 tumor cells were plated on the 
top of the BM in DMEM medium supplemented 
with 2% FBS. DMEM supplemented with 10% 
FBS was used as a chemoattractant in the lower 
chamber. After 4 days of incubation at 37ºC, the 
samples were washed with PBS, fixed with 4% 
paraformaldehyde 40min at room temperature, 
and stained at both membrane sides with 
phalloidin and DAPI for two hours. After staining, 
the whole insert was mounted on a glass bottom 
dish. Migrating/invading cells were imaged with 
a 20x objective of a laser-scanning confocal 
microscope (Leica SP8.) 3 to 5 random areas 
were imaged per sample and experiments 
were performed in three independent runs. 
Quantification of cell invasion was performed 
by counting the total number of nuclei/actin 
protrusions existing in the lower side of the BM, 
and they were expressed as a ratio with respect 
to the total number of nuclei in each area, 
indicator of cell number for each experiment. 
Images, z-sections, 3D reconstructions, and 
quantifications were performed with Fiji (ImageJ).
Experimental metastasis assays
HCT116 control or shTalin1 cells (5x105 in 0.1 ml of 
sterile PBS) stably expressing luciferase reporter 
were injected into the left ventricle of the heart of 
female nude mice, aged 7 weeks (nu/nu, Charles 
River) under 2,5% isoflurane/air anesthesia. 
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Only mice with evidence of a satisfactory 
intracardiac injection, indicated on day 0 by 
systemic bioluminescence distributed throughout 
the animal, continued in the experiment. 
Metastasis formation was monitored every week 
by bioluminescent imaging with a Xenogen IVIS 
(IVISR Lumina II) system coupled to Living 
Imaging software 4.2 (Xenogen Corporation). 
Luciferin (150 mg/kg in PBS; Firefly Luciferin, 
Caliper Lifescience Corp, Hopkinton, MA, U.S) 
was injected intraperitoneally as the substrate 
for the luciferase. Mice were sacrificed after four 
weeks and metastasis were macroscopically 
visualized and confirmed by luminescence 
emission. All tumor-bearing tissues were 
collected, fixed in 4% formalin, and embedded 
in paraffin. Haematoxilin-Eosin staining was 
performed to determine the presence of 
metastasis.  Mice were housed and maintained 
under specific pathogen-free conditions and 
used in accordance with institutional guidelines 
and approved by the Committee for Animal 
Care from the Universidade de Santiago de 
Compostela (USC). 
CellSearch CTC quantification in mice
To further explore distant dissemination, a 50µl 
of peripheral blood sample was extracted before 
mice sacrifice and tested for the presence of 
CTCs with the CellCaptureTM CTC Mouse Kit 
(Veridex LLC, Janssen Diagnostics). Briefly, 
mice blood was mixed with 25µl of Anti-EpCAM 
ferrofluids and incubated for 15 minutes. After 
immunomagnetic capture and enrichment, CTC 
were immunofluorescent staining using Anti-
Cytokeratins 8, 18 and 19 and DAPI. Analysis 
and enumeration of CTC was performed by an 
experienced user using the CellTracks Analyzer 
II® (Veridex LLC, Janssen Diagnostics). 
CTCs immunoisolation and qPCR 
quantification in mCRC patients
Circulating tumor cells were indirectly quantified 
in blood from 50 mCRC patients as previously 
described 273. Blood from 20 healthy volunteers 
was extracted and analyzed as control samples. 
Briefly, CTCs were immunoisolated from 7,5ml of 
peripheral blood using magnetic beads coated 
with an antibody towards EpCAM (CELLection 
Epithelial Enrich, Life Technologies) following 
manufacturer’s instructions. Total CTC RNA 
was extracted with the QIAmp viral RNA 
mini kit (Qiagen) and cDNA was synthesized 
using SuperScriptIII (Life Technologies). To 
further optimize the sensibility of detection, 
a preamplification step was performed 
using TaqMan PreAmp Master Mix kit (Life 
Technologies). Talin1 and Protein Tyrosine 
Phosphatase Receptor Type C (PTPRC or 
CD45) expression was quantified by real time 
quantitative PCR using hydrolysis probes (Life 
Technologies) in a StepOne Plus thermocycler 
(Life Technologies). Every sample was run in 
duplicate for each gene and appropriate negative 
controls were included in each qPCR reaction 
plate. Cq values (defined as the cycle number at 
which the fluorescence reached a fixed threshold 
value) for each transcript were normalized to 40 
(maximum number of cycles), and this value to 
the 40-Cq value for CD45 [(40-Cq target)-(Cq 
CD45)], used as a reference gene as it detects 
hematopoietic cells unspecifically isolated. We 
previously reported the validity of CD45 as a 
reference gene 273 as its expression levels are 
equal in patient and healthy donor samples. 
Gene expression analysis in primary tumors 
and metastatic tissue
Primary colorectal carcinomas (n=8) and 
metastasis (liver metastasis, n=7; lung 
metastases, n=7) were processed by the 
Pathology Department of the Complexo 
Hospitalario Universitario of Santiago de 
Compostela. The superficial non-invasive zone 
and the deep invasive area of the primary tumors 
were macroscopically dissected, ensuring similar 
tumor percentages. RNA was purified (TRIZOL 
reagent, Invitrogen; RNeasy kit, Qiagen), cDNA 
was synthesized (MuLV reverse transcriptase, 
Life Technologies), and gene expression 
was evaluated using hydrolysis probes (Life 
Technologies). Data was represented as 
fold change relative to the expression in the 
superficial non-invasive area. GAPDH, ACTB 
and RLPLO housekeeping genes were used as 
loading controls. 
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Data analysis
Differences between groups were assessed by 
applying Mann-Whitney non-parametric t-tests. 
In the cases were data were normalized to the 
relative values of ShControl cells, Wilcoxon-
signed rank test. For survival analysis, prognostic 
groups were set based on Talin1 CTC expression 
levels. Single patients were included into low or 
high-Talin1-CTC groups if Talin1 levels were, 
respectively, below or above cutoff, defined as 
the 75% percentile. Kaplan-Meier (KM) and 
univariate COX regression survival analysis 
were used to study associations between Talin1 
expression levels and PFS/OS. All statistic tests 
were performed with SPSSv20.0 and GraphPad 
prism v5 software and considered significant 
when p≤0.05.
Results
Talin1 is expressed in CTCs from 
mCRC patients and mediates tumor 
cell adhesion to endothelial cells and 
transendothelial migration
Previously, we showed that, among other 
genes, Talin1 is expressed in CTCs coming 
from CRC patients bearing metastasis. Here 
we validate those results in a bigger cohort (50 
mCRC patients and 20 healthy donors), and we 
confirmed that Talin1 was specifically expressed 
in CTCs coming from mCRC patient’s blood 
(Supplementary Figure S1A) (p<0,01). Talin1 
expression effectively discriminated mCRC 
patients from healthy controls, as evidenced by 
ROC curve analysis (AUC: 0,816, p=0,0017) 
(Supplementary Figure S1B). 
Figure 1. Talin1 influences cancer cells extravasation-related abilities. A) Western blot showing Talin1 protein expression 
in ShControl and ShTalin1 HCT116 and CT26 cells. Α-Tubulin was used as loading control. B) Relative Talin1 gene expression 
levels of ShControl cells compared to ShTalin1 (HCT116 and CT26) measured by qPCR. GAPDH was used as loading control. C) 
HCT116 and CT26 ShTalin1 cells adhesion to a HUVEC monolayer, normalized to adhesion of ShControl cells. D) Flow adhesion 
assay setup. Cells were maintained at 37ºC under agitation and forced to flow through a closed culture chamber system, over 
a HUVEC monolayer using a syringe pump. E) Representative images of HCT116 and CT26 cells (Control and Talin1 depleted) 
adhering to HUVECs under flow conditions. Cancer cells were labelled with Calcein AM, and represented on red. HUVE cells 
were imaged in bright field. Bars 100μm F) Tumor cell-HUVEC adhesion quantification for HCT116 and CT26 cell lines, from three 
independent assays. Adhesion of ShTalin1 cells is represented normalized to ShControl cells adhesion for both cell lines. G). 
Representative images of membrane protrusions formation in CT26 cells (ShControl and ShTalin1) after 1 hour of flow adhesion. 
Bars: 50μm. (H, I) HUVEC monolayer integrity assays. Endothelial cell retraction was measured in the XCELLigence system 
under the presence of ShControl or ShTalin1 HCT116 H) or CT26 I) cells, based on Cell Index reduction over time. Quantification 
of endothelial retraction (Cell Index slope during analyzed time) is represented in right panels for each cell line. J) Transendothelial 
migration of CT26 cells (ShControl and ShTalin1) after 24 hours of coculture with HUVECs. 
(*): p<0,05, (**): p<0,01, (***): p<0,001
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The first barrier that a CTC must overcome to 
escape the circulation and possibly establish 
a metastasis in a distant organ is the luminal 
endothelial layer of blood vessels. As Talin1 was 
found to be expressed in CTCs, we sought to 
evaluate its potential role in the steps involved 
in the process of CTC extravasation from the 
circulation. For that, Talin1 expression was stably 
knocked-down in two different cell lines (HCT116 
and CT26) by shRNA lentiviral delivery (Figure 
1A, B). Moreover, and as a model of endothelial 
cells, Human Umbilical Vein Endothelial Cells 
(HUVECs) were used.
After Talin1 depletion, both HCT116 and CT26 
cells, showed a significantly decreased ability 
to attach to a preformed HUVEC monolayer, 
in a static adhesion assay, when compared 
with control cells (Figure 1C). In order to mimic 
the physiological conditions of a CTC being in 
the bloodstream, we analyzed the adhesion 
capacities of Talin1 depleted cancer cells in a flow 
adhesion assay. Tumor cells were flowed over 
an endothelial monolayer during a determined 
time period, and the final percentage of cells 
adhering the HUVEC layer was quantified. 
Using this setup (Figure 1D) we found that both 
HCT116 and CT26 Talin1-depleted cells failed 
to attach to the endothelial cell monolayer under 
flow conditions, when compared with control 
cells (Figure 1E, quantification in 1F). Moreover, 
and specially for the highly invasive CT26 cells, 
ShControl cells were able to attach and formed 
membrane protrusions, that could be helping in 
the following steps of transmigration through the 
endothelial layer. However, in the case of Talin1 
depletion, even though some cells succeed to 
attach to the HUVEC layer, they formed fewer 
membrane protrusions (Figure 1G). 
An important step in the process of tumor 
cell extravasation from the circulation, after 
attachment to the vascular endothelium, is the 
retraction of endothelial cells to enable cancer 
cell migration between them before reaching 
the underlying basement membrane. To check 
whether Talin1 could influence endothelial 
retraction, we performed an endothelial 
monolayer integrity assay. A monolayer of 
HUVECs was formed in the wells of an E-plate 
(XCELLigence system, Roche), and then 2x104 
cancer cells were added and cocultured with 
endothelial cells. Figures 1H and I represent 
the normalized impedance signal obtained for 
each cell line (HCT116 and CT26, respectively) 
from the moment of cancer cell addition. 
When no cells were added to the monolayer of 
HUVECs, cell index (a direct indicator of the total 
percentage of the plate occupied by cells) was 
maintained over time, or even slightly increased 
(black lines). After the addition of cancer cells, 
cell index rapidly decreased, possibly due to the 
disruption of endothelial junctions and retraction 
of the endothelial monolayer (Figures 1H and I, 
red lines), as quantified by the slope decrement 
of each line over the analysis time (Figures 1H 
and I, right panels). Both for HCT116 and CT26 
cells, Talin1 depletion lead to a reduction in 
endothelial monolayer retraction (Figures 1H and 
I, blue lines, quantification in right panels). These 
results, suggest that Talin1 could be relevant 
for the initial steps of CTC transmigration 
through the endothelial barrier. Finally, we found 
that ShTalin1 CT26 cells were significantly 
less efficient in migrating through a HUVEC 
monolayer, when compared with control cells, in 
a TEM assay (Figure 1J). 
Together these results indicate that Talin1 plays 
a role in the extravasation step of CTCs from the 
circulation by influencing both the adhesion and 
transmigration of cancer cells to an endothelial 
monolayer.
Cancer cell adhesion to endothelial cells 
partially depends on FAs-endothelial 
fibrillary fibronectin contacts
Several cell adhesion molecules (CAMs) mediate 
the connection between cancer cells and 
endothelial cells 312. For example, VCAM, ICAM 
or L1 molecules, expressed by the vascular 
endothelium, interact with α4β1 integrin, CD44 
or αvβ3 receptors present on different cancer 
cells. Talin1 is involved in formation of cell-matrix 
adhesions, however, little is known about its role 
in cell-cell attachment. Here we hypothesize 
that, al least in part, adhesion of cancer cells to 
the endothelial layer could be mediated through 
the interaction of cancer cell FAs with the ECM 
produced by endothelial cells at their surface. 
To this regard, we found a large amount of 
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fibrillary fibronectin deposited on the surface of 
endothelial cells (Figure 2A), that could serve as 
docking points for cancer cells attachment. In fact, 
when CT26 (ShControl and ShTalin1) expressing 
Paxillin-GFP, another FA-complex protein, were 
seeded on top of the endothelial monolayer, 
we found that control cells formed numerous 
focal contacts with fibers present on the HUVE 
cells (Figure 2B). Moreover, antibody blocking 
of endothelial fibronectin lead to a reduction of 
CT26 adhesion to the endothelial monolayer 
(Figure 2C). Most of the Talin1 depleted cells, 
were washed out during the immunofluorescence 
process, with only few rounded cells remaining 
attached to the monolayer, suggesting that were 
not able to establish firm contacts with endothelial 
cells (data not shown). 
Together, these results indicate that attachment 
of tumor cells to the endothelium is partially 
dependent on FAs-fibronectin interaction, and 
could represent an additional mechanism for 
CTC adhesion to endothelial cells prior to 
transendothelial migration, with Talin1 as a key 
component for the correct formation of those 
contacts. 
Talin1 knockdown alters FA number 
and dynamics, adhesion to ECM and 
migration of cancer cells
To gain a mechanistic insight into the role of Talin1 
in cancer cell extravasation, we investigated the 
effect of Talin1 depletion on FA formation and its 
relation with cell adhesion and migration abilities. 
Talin1-depleted cells showed a significant 
reduction in the number of FAs formed when 
plated onto fibronectin-coated surfaces, as 
evidenced by Talin1 and Vinculin staining (Figure 
3A, quantification in 3B), which directly implies 
a defect in cell spreading (Figure 3A, phalloidin 
staining). No changes in FA size were found, 
although HCT116 ShTalin1 cells tended to form 
bigger adhesions (Figure 3C). Talin1/Vinculin 
positive aggregates were still observed after 
knockdown of Talin1, which suggests a non-
complete depletion of Talin1 (Figure 3A).
To investigate whether the reduction of Talin1 
expression levels in CRC cell lines could 
influence FA turnover, the dynamics of CT26 
ShControl and ShTalin1 Paxillin-GFP cells were 
followed over time by spinning disk microscopy. 
In ShControl CT26 cells, FAs formed and 
disassembled in 25 minutes on average. 
However, in Talin1 depleted cells, FAs displayed 
a significantly shorter turnover time (≈12min) 
(Figure 3D, quantification in 3E). This alteration 
of FA turnover in Talin1-depleted cells had a 
direct implication on stabilization of membrane 
protrusions (Figure 3F). ShControl CT26 cells 
generated broad and stable protrusions, which 
protruded and retracted in 70-80min on average. 
In Talin1-depleted cells, protrusions were less 
stable, with significantly shorter lifetime, about 
≈25min (Figure 3G) (Supplementary Movie S1). 
Functionally, Talin1 knockdown significantly 
decreased cell adhesion to fibronectin-coated 
Figure 2. CRC CT26 cells adhere to HUVECs by FA 
interaction with fibronectin fibers produced by endothelial 
cells. A) Confocal HUVECs images stained for fibronectin 
(green) and phalloidin (F-Actin) (red). Lower panel represents 
a Z section of a single HUVE cell showing fibrillary fibronectin 
production on the top surface of the cell. Bars: 20μm. B) 
Immunofluorescence of CT26 ShControl and HUVECs 
cocultures. Cancer cells were transfected to express Paxillin-
GFP (green). HUVECs cells were stained for fibronectin (red). 
Cell nuclei were DAPI stained (blue). Colocalization of paxillin-
GFP labelled FAs with HUVECs fibronectin fibers was found 
(white arrows, lower panel blowup). Bars: 20μm C) CT26 
ShControl cells adhesion to HUVECs after antibody blocking of 
fibronectin. Results are represented relative to IgG treatment. 
(*): p<0,05.
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surfaces, and to different other extracellular 
matrices including Collagen (I, II and IV), 
Laminin, Tenascin and Vitronectin (Figure 3H), 
as a direct consequence of the reduced FA 
formation. To assess the effect of Talin1 depletion 
on cell migration, we first performed 2D migration 
assays in fibronectin-coated culture surfaces 
(Figure 3I). After 8 hours, ShControl CT26 cells 
displayed migration paths of approximately 
400μm and an average speed of 0,8μm/min, 
while Talin1-depleted cells migrated significantly 
faster (≈1,2 μm/min) and at longer distances 
Figure 3. Talin1 regulates FA number, turnover, cell adhesion and migration. A) Focal Adhesions (FAs) immunofluorescence 
(Talin1 and Vinculin) in HCT116 and CT26 control and Talin1-depleted cells. Phalloidin staining was used to image F-Actin, and 
DAPI as nuclear labeling. Bars: 20μm  B) FA number and size C) quantification based on Vinculin staining in HCT116 and CT26 
control and Talin1-depleted cells. D) FA turnover in CT26 ShControl and ShTalin1 cells, expressing Paxillin-GFPTime in minutes. 
E) Quantification of FA turnover time. F) Lifetime of cellular protrusions in CT26 ShControl and ShTalin1 cells. G)  Quantification 
of membrane protrusions lifetime. H) HCT116 and CT26 (control and ShTalin1) adhesion to different ECM substrates at indicated 
incubation times.  I) Migration paths of CT26 (control and Talin1-depleted) on fibronectin-coated 2D surfaces. Representative 
migration diagram of a single experiment. Quantification of path length J) and cell velocity K) from three independent experiments. 
L) Transwell migration of HCT116 and CT26 cells (24 and 72 hours of migration, respectively) 
(*): p<0,05; (**): p<0,01; (***): p<0,001
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(≈600 μm) (Figures 3J and K) (Supplementary 
Movie S2). Thus, more dynamic FAs and 
protrusions in Talin1-depleted cells support their 
faster migration. No differences were found 
in cell persistence between control and Talin1 
depleted cells (data not shown). Interestingly, 
using a transwell assay, we found that, ShTalin1 
cells were significantly less effective in migrating 
through the porous membrane of the transwell 
insert compared to control cells (after 24 and 72 
hours, respectively) (Figure 3L). 
Together, these results show that Talin1 
influences FA formation and turnover, which 
consequently regulates cell adhesion to the 
ECM and the maintenance of cellular protrusions 
modifying cell migration ability.
Talin1 depletion decreases cancer cell 
invasion in a native basement membrane 
in vitro model
After transendothelial migration, cancer cells 
must be able to invade the extracellular matrix 
underlying the endothelial layer. To further 
investigate the role of Talin1 on cancer cell 
invasion, we performed a native BM invasion 
assay. Experiments were performed as previously 
described by Schumacher et al 314 (scheme in 
Figure 4A), replacing the porous membrane of a 
transwell insert with the peritoneal BM obtained 
from mice, which is structured in two well-defined 
laminin layers, surrounding an intermediate layer 
reach in collagen. CT26 ShControl or ShTalin1 
cells were seeded on top of the membrane and 
incubated for 4 days. After this time, we found 
that Talin1 depleted cells were less effective 
in terms of BM invasion when compared with 
control cells (Figure 4B) as both the number 
of actin protrusions breaking through the BM 
structure and the number of traversing cell nuclei 
were significantly reduced in Talin1 depleted 
cells (Figure 4C and D) (Supplementary Movie 
S3). Together, these results suggest that Talin1 
could be implicated in cell features regulating 
invasiveness, reinforcing its role in later 
extravasation steps. 
Talin1 depletion reduces metastasis 
formation in an in vivo tumor 
dissemination model
To investigate how the expression of Talin1 
could be modulating the metastatic potential of 
CTCs, we injected in the left heart ventricle of 
nude mice, HCT116 control and Talin1-depleted 
cells, mimicking the conditions of a CTC while 
in the bloodstream. HCT116 ShControl cells 
Figure 4. Talin1 knockdown reduces native basement membrane invasion ability of cancer cells. A) Schematic 
representation of native basement membrane invasion experiments setup. B) Representative confocal Z sections of a native 
basement membrane CT26 ShControl and ShTalin1 cells. Basement membrane was visualized by reflectance (green). Cell 
nuclei were DAPI stained (blue), and F-Actin was stained with Phalloidin (red). Quantification of invading CT26 cells from three 
independent assays. C) Invading actin protrusions of ShTalin1 cells compared to ShControl. D) Relative invading nuclei of 
ShTalin1 cells compared to ShControl
(**): p<0,01; (***): p<0,001
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effectively survived in the circulation and rapidly 
formed tumors, mainly in bone tissue, adrenal 
glands and ovaries (Figure 5A, upper panels). 
HCT116 ShTalin1 failed to form metastasis when 
compared with control cells (Figure 5A, lower 
panels), with significantly less affected organs 
(Figure 5B). This effect was not due to proliferation 
differences between control and Talin1-depleted 
cells (Supplementary Figure S2). Interestingly, at 
the moment of sacrifice (28 days post injection) 
no CTCs were detected in ShTalin1 injected 
mice, while 2 out of 5 mice (40%) were positive 
for CTC count. Similar results were obtained with 
an independent ShTalin1 clone (data not shown). 
Together these results show that Talin1 is an 
essential molecule to allow organ colonization 
by tumor cells from the bloodstream and thus, 
relevant in terms of CTC biology.
Talin1 expression correlates with patient 
prognosis, therapy response and tumor 
progression in mCRC
To finally validate our hypothesis of Talin1 as a 
CTC marker and a potential therapeutic target 
against cancer dissemination in mCRC, we 
analyzed the expression levels of Talin1 in a set of 
50 samples of immunoisolated CTCs from blood 
of mCRC patients at baseline, before the onset 
of a given chemotherapy. High or low Talin1 CTC 
expression levels were defined based on the 75% 
percentile of the global Talin1 expression data 
from the whole patient set. Kaplan-Meier analysis 
revealed that patients with High-CTC-Talin1 had 
a mean Progression Free Survival (PFS) time of 
6,9 months, and Overall Survival (OS) of 10,5 
months, compared to 12,3 (PFS) or 24,6 (OS) 
months for patients classified as Low-CTC-Talin1 
(Log-Rank test: PFS: p=0,004; OS: p=2x10-5) 
(Figures 6A and B). Hazard Ratio (HR) for High-
CTC-Talin1 patients was 2,63 for PFS and 4,47 
for OS, compared with Low-CTC-Talin1 patients, 
as calculated by Cox regression analysis (PFS: 
p=0,010; OS: p=0,0003). Together these results 
validate the utility of Talin1 expression levels in 
CTCs as a prognosis marker in mCRC.
To investigate the role of Talin1 as a predictive 
marker for therapy effectiveness monitoring in 
mCRC patients, we evaluated its expression 
in CTCs in the previous set of patients after 
the administration of a first-line chemotherapy. 
All patients were analyzed after 4 weeks after 
therapy onset (one chemotherapy cycle). When 
required, a third sample was collected before 
cycle 5 (≈week 16). Patients were considered 
responders (R) when classified as CTC-Talin1-
Low both at baseline and 4 weeks. Patients at the 
High-CTC-Talin1 group at both time points were 
classified as non-responders (NR), together with 
those moving from the Low-CTC-Talin1 group at 
baseline to the High-CTC-Talin1 one at 4 weeks. 
Finally, patients changing from the High-CTC-
Talin1 group at baseline to the Low-CTC-Talin1 
Figure 5: Talin1 knockdown reduces metastasis formation of human CRC cells in a tumor dissemination mouse 
model. A) Representative images of HCT116 ShControl and ShTalin1 cells, expressing a luciferase reporter gene, injected 
intracardiacally in Nude mice. Injection control (day 0) is represented in top left panel. Right panels represent metastasis formation 
for both cell lines overtime. B) Quantification of number of metastatic foci per mouse for ShControl and ShTalin1 cells. (*): p<0,05 
C) CellSearch (Veridex) CTC quantification in injected mice at sacrifice day (28 days).
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one at 4 weeks were preventively included in the 
group of responders and a confirmatory sample 
was drawn before cycle 5 of chemotherapy. If 
those patients were corroborated as Low-CTC-
Talin1, they were classified as responders; 
on the contrary, they were considered as non-
responders if the third sample resumed to the 
High-CTC-Talin1 group (scheme in Figure 6C). 
Kaplan-Meier survival analysis showed that 
patients classified as responders based on the 
expression levels of CTC Talin1 along treatment, 
Figure 6. Talin1 expression in CTCs is a prognosis and predictive marker in mCRC patients. Kaplan-Meier survival plots 
for Progression Free Survival (PFS) A) and Overall Survival (OS) B) for mCRC patients with High or Low Talin1 expression 
in CTCs at baseline. C) Schematic representation of mCRC patient’s classification in therapy responders (R) or non-responders 
(NR) based on Talin1 expression in CTCs during treatment. Kaplan-Meier survival plots for PFS D) and OS E) for patients 
classification into therapy responders (R) or non-responders (NR) based on the variation of Talin1 expression in CTCs along 
treatment. F) Talin1 gene expression in the invasive front of CRC primary tumors, relative to the non-invasive area. G) Talin1 gene 
expression in CRC metastatic lesions (lung and liver) from primary CRC carcinomas, relative to its expression in the non-invasive 
tumor area of primary tumors.
 (**): p<0,01; (***): p<0,001
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had a mean PFS of 12,6 months (24,6 months 
for OS), compared with 6,6 months for the group 
of non-responders (11,5 months for OS) (Log-
Rank: PFS: p=0,005, OS: p=4x10-4) (Figures 
6 D and E). Hazard Ratio (HR) for the group of 
non-responders was 2,47 for PFS and 3,47 for 
OS, compared with Low-CTC-Talin1 patients, 
as calculated by Cox regression analysis (PFS: 
p=0,012; OS: p=0,002). Together these results 
highlight the value of Talin1 expression levels 
in CTCs as a predictive marker for therapy 
response evaluation in mCRC patients.
Finally, and to analyze Talin1 expression 
correlation with tumor progression, we evaluated 
Talin1 gene expression levels in the invasive 
and non-invasive areas of a series of 7 primary 
CRC tumors, and in 14 liver and lung metastasis 
of independent patients sets. The expression 
of GAPDH, ACTB and RPLPO housekeeping 
genes, was also analyzed as loading controls. We 
found a significant 1,7-fold Talin1 upregulation 
(p<0,01) in the invasive area of primary colorectal 
carcinomas, relative to the non-invasive area 
of the same tumor (Figure 6F). A mean 4-fold 
Talin1 upregulation (p<0,001) was found in liver 
and lung metastatic tissue when compared with 
the non-invasive area of the primary tumors set 
(Figure 6G). As a whole, these results indicate a 
possible gradual increment of Talin1 expression 
in tumor cells as tumor progression moves 
forward. 
Discussion
Approximately 90% of all cancer related deaths 
arise from the metastatic spread of tumors, 
which turns metastatic disease formation as 
the most clinical, but less understood, aspect 
of cancer progression 315. In CRC, escape of 
malignant cells from the primary tumor to reach 
the circulation, constitutes one of the main 
routes for cancer dissemination, with liver as the 
principal target site for metastasis formation 306. 
During the last years, the scientific community 
has greatly focused in the study of CTCs as a, 
although not definitively proved, highly probable 
responsible for cancer spreading towards distant 
sites through the bloodstream. Indeed, mCRC 
patients with 3 or more CTCs per 7,5mL of 
blood displayed a significantly reduced survival, 
when compared with those having 2 or less 
CTCs, which indicates the prognostic role of 
CTC measurement 76,80. Based on clinical data, 
molecular analysis of CTCs has increasingly 
gained attention. From the very first CTC 
gene expression profile published in 2005 211, 
several groups have focused on the genomic, 
transcriptomic and functional characterization of 
CTCs, in order to obtain a more comprehensive 
picture of the metastatic process from a minimally 
invasive liquid biopsy 171,172,179. 
CTC extravasation constitutes the first step of 
the process of distant organ colonization from 
a cell being in the bloodstream. Although widely 
studied in leucocytes, as the normal process 
for cell exit from the circulation at inflammation 
sites, much less in known about extravasation 
in cancer metastasis 150,312. In this regard, CTC 
characterization could provide more detailed 
information about specific molecules involved 
in the regulation of this process. We have 
recently published a set of mCRC CTC-specific 
genes 213, that mainly comprised genes related 
to adhesion pathways, reinforcing the role of 
adhesion-related molecules for CTC biology. 
From these results, we selected Talin1 as a 
potential extravasation-driving gene, and thus, 
as a metastasis-related marker and a putative 
therapeutic target against cancer dissemination. 
In the present study, we analyzed the role of 
Talin1 on cancer cell adhesion, invasion and 
migration, specially focusing on cellular features 
related to CTC extravasation. 
The first barrier that a potentially metastatic 
CTC finds in the process of escape from the 
circulation is the luminal endothelial layer of 
blood capillaries. During extravasation, cancer 
cells must dynamically interact with endothelial 
cells to finally transmigrate through them into 
the underlying matrix and stroma 312. It has been 
hypothesized, based on in vitro observations, 
that CTCs may roll over the endothelial layer, in 
an early process termed “docking”, (mediated 
by cancer cell glycoproteins and corresponding 
endothelial selectins), and later establish firmer 
adhesions with endothelial cells (“locking”) 
(usually mediated by CAMs and integrins) before 
final transendothelial migration 312,313,316. Here we 
show that Talin1 depletion significantly reduces 
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tumor cell adhesion to HUVE cells, used as a 
model of endothelial blood vessel layer, both under 
static and more physiological flow conditions. 
Adhesion times used in these experiments 
were relatively short, indicating a possible role 
for Talin1 in the early “docking” step, probably 
through activation of integrins in the plasma 
membrane. We also found that, mimicking later 
steps of cancer cell extravasation, Talin1 failed 
to form membrane protrusions that could allow 
cancer cells to squeeze in between endothelial 
cells, with a posterior consequence in endothelial 
cell retraction, and finally in transendothelial 
migration. As observed in vitro, reduction in FA 
turnover time after Talin1 depletion could explain 
the reduced ability of those cells to establish 
membrane protrusions over the endothelial layer. 
Moreover, β1 integrins (commonly activated 
through Talin1 and expressed in HCT116 and 
CT26 cells) have been related to the process 
of endothelial cell retraction by the induction of 
VE-cadherin phosphorylation, which dissociates 
β-catenin from the VE-cadherin complex, finally 
disrupting endothelial adherens junctions in 
breast cancer 317. Although not proven, we 
speculate that a similar mechanism could be 
occurring in our CRC model. 
As mentioned, attachment of cancer cells to 
the endothelium prior to extravasation relies on 
the interaction between endothelial selectins 
and CAMs with their cancer cells counter-
receptors (SLeX glycoproteins and β1 and β3 
integrins, among others) 120,150,312,313. Here, we 
showed an additional attachment mechanism, 
mediated by the expression of fibronectin 
fibers on the surface of endothelial cells, which 
colocalized with cancer cells FAs, accounting 
approximately for 20% of cancer cell-endothelial 
adhesiveness, as demonstrated by antibody 
blocking of endothelial fibronectin. To our 
knowledge, this is the first work reporting these 
types of contacts, which could represent a 
novel mechanism for CTC firm adhesion to the 
endothelium, prior to TEM. The involvement of 
Talin1 in this particular mechanism relies on the 
reduced ability of cancer cells to form FAs after 
Talin1 depletion, and thus, the establishment of 
endothelial-cancer cells contacts through FA-
fibronectin interactions. Interestingly, data in lung 
cancer suggested that plasma fibronectin could 
confer a pro-metastatic ability to cancer cells 
by activating αVβ3 integrins, further promoting 
tumor cell invasion 318. To this regard, production 
of fibronectin at endothelial cells surface and/
or deposition of circulating plasma fibronectin 
could also be mediating metastasis formation by 
promoting CTC extravasation.
Cell adhesion strength and migration speed 
have been related in a biphasic manner 
319,320. Migration velocity increases from low to 
medium adhesion strengths, while an excessive 
increment in cell adhesion causes a dramatic 
reduction in cell movement. Talin1 depletion 
directly causes an increase in cell speed in 2D 
fibronectin coated substrates, probably due to 
a reduction in adhesion strength, likely caused 
both by a reduction in FA number and turnover. 
In contrast, Talin1 depletion decreased the ability 
of cells to migrate in a Transwell assay. This can 
be explained because the formation of mature 
and stable FAs (absent in Talin1 knockdown) is 
a necessary event for the interaction with the 
cellular acto-myosin cytoskeleton, which can 
transmit cell-substrate traction throughout the 
cell 321, further allowing migration through the 
pores of the Transwell insert. Because a gradient 
of FBS was established to perform this kind of 
assays, one could speculate that the reduced 
expression of Talin1 in cancer cells could also be 
influencing directional migration of cells towards 
a chemical gradient. However, no differences in 
directional migration were found for CT26 cells 
in Dunns chemotaxis assays (data not shown), 
discarding a role for Talin1 in chemotaxis.
After TEM, CTCs must deal with the presence 
of the endothelial basement membrane, invading 
through it to effectively colonize the final 
metastatic site. To address the role of Talin1 in 
this later step, we used a native BM invasion 
assay, which represents the closest model to 
the in vivo situation, as a native mouse BM is 
used. Reduced expression levels of Talin1 led 
to a significantly reduced invasion ability of the 
highly invasive CT26 CRC cell line, suggesting 
an important role for Talin1 in this process. 
Cancer cells used F-actin-based structures 
called invadosomes to establish close contact 
with the ECM and invade through it, due to 
their ability to degrade ECM components 322. 
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As Talin1 is involved in invadosome formation, 
we hypothesize that reduced ability of CT26 to 
invade BM structures could be, at least in part, 
due to a reduction in invadosomes number and/
or activity. Matrix degradation assays, as well 
as Matrix Metalloproteinases (MMP) expression 
analysis would be of great interest to elucidate the 
mechanism by which Talin1 could be modulating 
cell invasiveness. These results, together with 
the reduced ability of Talin1 depleted cells to 
adhere, induce retraction and TEM of endothelial 
cell monolayers, indicate the relevance of Talin1 
in the whole process of CTC extravasation from 
the circulation. 
Based on our in vitro observations, we analyzed 
the role of Talin1 in a mouse model of metastatic 
dissemination. Metastasis formation was 
dramatically decreased for human HCT116 
cancer cells, a better model than mouse CT26 
cells to test CRC dissemination, after Talin1 
depletion, with a reduced number of finally 
detected CTCs on injected animals. Clinically, 
we describe an association between Talin1 
and the sequential acquisition of an aggressive 
phenotype, based on Talin1 expression levels 
in primary and metastatic lesions, in agreement 
with some works that have already reported 
the role of Talin1 in cancer progression 140,311. 
Moreover, it has been shown to be a target for 
mir-9, a microRNA with tumor suppressor activity 
in ovarian carcinoma 323. These results, together 
with the observation that patients with high 
Talin1 expression in CTCs displayed much less 
survival times (PFS and OS) than those with low-
Talin1, reinforced the role of Talin1 as a CTC and 
metastasis marker and as a potential therapeutic 
target against cancer dissemination.
Importantly, we also found that Talin1 expression 
on CTCs had a predictive value, due to the fact 
that, variations in Talin1 CTC expression during 
treatment, predicted therapy response in terms of 
patient survival. Talin1 loss of function was previously 
associated to Docetaxel chemosensitivity in triple 
negative breast cancer 324 and elevated Talin1 
expression in metastatic cancer cells has also 
been linked to anoikis (detachment-induced cell 
death) resistance 140, and to TRAIL-induced 
apoptosis 325. Talin1 function could represent a 
mechanism by which CTCs acquire resistance 
to chemotherapy, explaining our patient survival 
data. It is also reasonable to hypothesize that, 
in our metastasis mouse model, Talin1 depleted 
cells could undergo anoikis after failure to attach 
the blood vessels endothelium. 
Currently, several experimental therapies are 
being tested in clinical trials, to assess the validity 
of targeting integrin activation, in which Talin1 is 
involved. αVβ3 binding inhibition to ECM was 
effectively blocked by small peptides (Cilengitide, 
EMD121974, Merck) or by monoclonal 
antibodies (DI17E6), showing promising 
results in clinical trials for different tumor types, 
including mCRC (DI17E6 in combination with 
Cetuximab, NTC01008475) 326. Based on our 
results, here we propose Talin1 as a direct target 
for pharmacological inhibition, especially for the 
treatment of metastatic disease.
In summary, the evidence presented supports a 
particular role for Talin1 in circulating tumor cell 
extravasation, through the specific interaction 
with blood vessels endothelial cells, mediating 
adhesion, transendothelial migration and further 
basement membrane invasion, which finally 
results in metastasis formation. Our clinical data 
suggest Talin1 as a valuable marker both to 
predict patient prognosis based on Talin1 levels 
in CTCs, but also as a tool to monitor treatment 
effectiveness in mCRC. Further studies will 
pursue the evaluation of specific Talin1 inhibitors, 
what will place this molecule in a relevant 
condition to be considered as a new therapeutic 
target to tackle metastatic spreading. 
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Colorectal cancer (CRC) represents the third most diagnosed cancer type worldwide, 
accounting for more than 600.000 deaths in 2012, which approximately represents 8,5% 
of all cancer-related deaths 1. Taking into account that incidence rates are still continuously 
increasing in developing countries 3,4, research in CRC screening, diagnosis and treatment 
is underscored. 
During the last years, significant advances have been made in the early detection and 
treatment of localized CRC, which has importantly contributed to the reduced mortality 
rates and allowing for five-year survival rates over 90% 7. However, the appearance of 
disseminated disease is still a milestone that invariably determines patient’s prognosis, 
with reduced 5-year survival rates that reach 10% in the worst cases 7. This makes the 
occurrence of metastasis the main actual bottleneck in the management of CRC patients. 
In this regard and despite patients with advanced CRC stages cannot routinely undergo 
surgery, progress in the discovery of new therapeutic agents have substantially improved 
survival rates and general patient welfare. However, the development of more specific 
and active cancer drugs, must go hand by hand with the establishment of new and more 
effective prognostic and predictive factors, to reliably estimate patient’s life expectancy, 
allow the selection of adequate therapies, and evaluate their response to anti-tumor agents.
Notwithstanding considerable achievements have been made to this regard, prognostic, 
and especially predictive markers often fail to show results close to the expected. This could 
be probably due to their analysis in primary tumor tissue samples, and not in metastatic 
lesions, which are those that truly determine the prognosis of this type of patients 328. 
Moreover, given that cancer is a continually evolving disease at the molecular level, it is 
controversial whether a single primary tumor biopsy at a specific time point represents 
the patient’s disease 329. Sequential analysis of primary tissue during the course of a 
given therapy, or the evaluation of molecular alterations in metastatic lesions would thus 
probably be a better indicator of tumor characteristics, leading to an optimized therapy 
response prediction. However, subjecting patients to serial invasive biopsies (from primary 
or metastatic tissues) is often impractical and confer a considerable risk to the patient 171. In 
addition, single site biopsies are unlikely to capture the complexity of the genomic landscape 
of a patient’s tumor, normally due to the presence of high intratumor heterogeneity 330. Thus, 
having a more comprehensive picture of the overall tumor content is required for a better 
patient management. The analysis of Circulating Tumor Cells (CTCs) provide innovative 
and promising solutions to these problems, as they can be quantified and characterized 
repetitively in a non-invasive way, through the obtaining of a simple blood sample, thus 
serving as a surrogate patient’s “liquid biopsy”.
CTCs correspond to tumor cells that have been shed into the bloodstream by primary tumors 
and, at least a subpopulation of these CTCs, has the ability for the generation of overt 
metastatic lesions 172. Moreover, CTCs found in the circulation can also come from distant 
metastases or bone marrow 117,169,170, proposing CTCs as metastatic intermediates and 
making their analysis of a great relevance for the better understanding of dynamic cancer 
complexity. CTC counts have been shown to predict CRC patient’s prognosis, among other 
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several cancer types 76,77,177, and can be also used as an early marker of therapy response 
108,109,112. Moreover, and considering the biological metastasis-related characteristics that 
CTCs potentially hold, their molecular characterization is expected to open a completely 
new avenue in the understanding of the life-threatening metastatic cascade. However, 
CTC detection, quantification and characterization methodologies, although promising, are 
still in their initial phases, and important steps forward are needed to fulfill the contribution 
of CTCs in oncology. In this thesis, we have described a number of advances in the field 
of CTCs, specifically in metastatic CRC, in terms of detection and quantification, global 
molecular characterization, identification of predictive CTC-related biomarkers and finally, 
in the elucidation of molecular determinants linked to the inherent CTC metastatic ability. 
CTC detection and quantification
Although several methodologies have been reported in the last years for CTC isolation from 
blood and their quantification, the CellSearch® system remains the gold standard method, as 
the only approved by the American FDA for CTC quantification in metastatic prostate, breast 
and colon cancers 76,199,200. As mentioned, the scarcity of CTCs, even in patients with overt 
metastases, together with the overwhelming number of peripheral blood mononuclear cells 
amongst which they have to be identified, evidences the need of more specific and sensitive 
CTC detection techniques. 
In the first part of this thesis we have developed an alternative method for CTC isolation and 
quantification based on the use of anti-EpCAM coated magnetic beads coupled to indirect 
CTC detection using qPCR-based selected markers (chapter II, page 65). 
Contrary to what happens in other tumor types, the frequency of EpCAM-negative colorectal 
tumors is low for all tumor stages, grades and histologies, which supports the use of 
EpCAM as a target molecule for CTC enrichment 331. However, cellular plasticity processes 
linked to EMT could be downregulating EpCAM before intravasation of CTCs, suggesting 
that at least a subpopulation of EpCAM-negative (EMT positive) CTCs could be lost using 
this methodology 305. While this may be so, EpCAM+ CTCs represent an essential CTC 
subpopulation with demonstrated metastasis formation abilities as reported by Baccelli et 
al 172. This, together with the widely evidenced prognostic value of the presence of EpCAM+ 
CTCs, as repeatedly reported in CellSearch®-based studies 77,80,177, clearly upholds EpCAM-
based CTC isolation in CRC, and reinforces the validity of our strategy. 
Even after CTC enrichment, a large number of unspecifically isolated cells are present in 
the sample, which hinders a reliable and specific CTC detection and quantification. In fact, 
technologies like CellSearch depend on the use of positive markers (in this case, cytokeratins) 
for the identification of CTCs, but also of lymphoid markers (e.g. CD45) to get rid of the noise 
produced by the presence of leucocytes in the sample 77,175-177. Taking this into account, we 
screened for genes which expression was previously reported as high in intestinal epithelial 
tissues, including VIL1, TBX20, GPA33, FAM132A, PREX2, EPCAM, CK20, TM4SF3, 
CDX2 and CDH17. Moreover, and to maximize CTC detection sensitivity, we included in 
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this method a preamplification step by which genetic material coming from EpCAM-enriched 
CTCs is moderately amplified before final qPCR. By applying this methodology, only VIL1, 
a gene encoding for the Villin protein, specifically expressed at the intestinal villus 332 and 
colorectal carcinomas 333, and thus detecting epithelial cells from intestinal origin, was found 
to be significantly expressed in CTCs to be detected above background. Interestingly, and 
even after CTC enrichment using anti-EpCAM magnetic beads, we could not find significant 
EpCAM expression in patient’s samples. However, expression of EpCAM protein at cell 
surface need not necessarily correlates with its mRNA expression. This, together with 
differential rates of RNA degradation between transcripts, might explain the lack of detectable 
EpCAM expression. We also included a probe for GAPDH, a housekeeping gene ubiquitously 
expressed, as an indicator of the global sample cellularity, and CD45, to evaluate the levels of 
leucocyte contamination. Importantly, expression levels of CD45 did not differ between patient 
and control samples, demonstrating similar levels of unspecificity between samples, and 
finally allowing its usage as a normalizer transcript to, at least partially, eliminate background 
noise present in the other two genes analyzed.  
By combining the expression of GAPDH and VIL1 (both normalized to CD45), we finally 
generated a CTC detection model that effectively separate mCRC patients from healthy 
volunteers, classifying 73% of mCRC patients as CTC positive. CTC positivity rates for the 
CellSearch® system in the same type of patients do not normally exceed 50% 334. This, 
together with the prognostic value found for these CTC-markers, clearly highlights the validity 
of our method for an improved CTC detection and quantification.
Moreover, the versatility of this technology, where different or additional probes can be 
incorporated for CTC detection in other malignancies, together with its reduced cost compared 
with other CTC-detection strategies, and its relative simplicity, are attributes that make it an 
interesting alternative for the evaluation of CTC burden in cancer patients. 
Advances in CTC molecular characterization
Going beyond CTC counting and employing their features as prognostic factors, the 
exploration of CTC molecular characteristics represents one of the most attractive, and at the 
same time challenging, actual aspects of CTC research. The evaluation of CTC-specific gene 
expression profiles would potentially shed light into the still largely unknown process of tumor 
dissemination, since they are considered as one of the main metastatic intermediates 117,169,170. 
Moreover, this type of analyses are of special interest as the obtaining of new CTC-derived 
biomarkers will provide with valuable tools for their detection and quantification, prognostic 
and predictive markers and, interestingly, potential therapeutic targets to specifically tackle 
CTCs and thus, metastatic spreading. 
Based on the CTC enrichment method previously described, and with the aim of having a 
wider picture of CTC transcriptional profile, we performed a global molecular characterization 
of CTCs from mCRC patients using gene expression microarrays, which interrogate a very 
large list of mRNA transcripts (chapter III, page 75).
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Despite the large information volumes that this kind of methodologies can yield, they still 
depend on the use of relatively high amounts of starting genetic material, which cannot 
normally be obtained from a CTC sample. To overcome these shortcomings, we performed 
a whole transcriptome amplification (WTA) method, to linearly amplify the total CTC RNA, in 
order to obtain enough material for further analysis. The optimization of this methodology, 
demonstrated the feasibility of the global molecular expression of limited-cellularity samples, 
and reinforces the compatibility of the previously described CTC enrichment/quantification 
method with subsequent molecular analyses. This allows the quantification of CTC burden 
at the same time that enables CTC profiling, in a single sample, which gives it an advantage 
over other relatively closed systems like CellSearch®.  
By comparing patient samples containing CTCs with normal blood from healthy volunteer 
samples, we finally obtained a set of 410 genes specifically expressed in the CTC population. 
Interestingly, the whole gene set was found to be positively expressed in patient’s samples, 
which fits the idea of having an extra cellular population (CTCs) in this sample type, absent in 
healthy donors, validating this strategy for CTC profiling. Of note, bioinformatic interpretation 
of the whole CTC-derived dataset, suggested a CTC phenotype based on cell adhesion, 
migration and invasion abilities, including at the same time transcripts previously associated 
with chemorresistance (ABCC3, ABCC4 or ABCC5 335), which, as a whole, indicated a 
potential CTC aggressive behavior.
Array results were validated in a larger sample (20 patients and 10 controls) by qPCR, for 
11 different transcripts (TGFβ1, APP, CD9, CLU, ITGB5, LIMS1, TIMP1, VCL and BMP6), 
selected based both on their relative expression levels (microarray signals) between control 
and patient samples, and on the cellular roles played by their encoded proteins. As we 
had previously hypothesized, all validated CTC-transcripts showed a significant prognostic 
value, and patients with higher marker expression levels displayed reduced progression 
free survival times, which confirms the potential clinical utility of CTC profiling. Of particular 
interest is the fact that most of those CTC-specific validated transcripts, were found to be 
sequentially upregulated during the process of metastatic dissemination (sequence invasive 
primary tumor-metastasis). As CTCs are supposed to be an intermediate step between 
primary tumors and the formation of overt metastases, the progressive upregulation of these 
genes in particular, but probably of more of those included in the whole array set, would 
probably be linked to the ability of these cells to escape the primary tumor and reach a target 
organ, through all the intermediate processes included in the metastatic cascade. 
However, and despite these results are promising, they must be carefully interpreted as we 
cannot ensure if gene expression differences between patients come from their intrinsic 
expression in CTCs, or merely depend on the number of CTCs that a single patient has. 
Future work must be done in this field to specifically assess the relative gene-expression 
levels of this gene-set in individual CTCs, which may then be directly compared with primary 
or metastatic tumor tissue.
Altogether, the results presented in the second part of this thesis highlight the importance 
of CTC profiling as a powerful strategy to identify markers linked to the metastatic process, 
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which, at se same time that provide clues of its molecular framework, allow the identification of 
prognostic factors that, once clinically validated, could help in the better patients management 
and stratification. 
CTC-markers for therapy response evaluation
Bearing in mind the relationship that has been extensively found between CTC counts and 
patient’s prognosis, one would expect that its quantification, together with their molecular 
characterization, might provide valuable insights for the individual treatment of cancer 
patients and its subsequent monitoring. 
As treatment has become more effective for colorectal cancer, decision-making has also 
become more complicated. The actual clinical standard considers a treatment change 
after several weeks or months if there’s evidence of progression. However, after initiation 
of systemic treatment, current methodologies, usually imaging, do not often allow for an 
accurate and early assessment of clinical benefit. Thus, patients may be either treated for 
prolonged periods with an inactive therapy or a potentially active therapy might be discontinued 
prematurely. CTCs have been proposed as a novel therapy response evaluation tool as they 
can be analyzed repeatedly during the course of a treatment from a minimally invasive blood 
sample. Changes in the number of CTCs along treatment have shown to identify patients 
showing a response to therapy from those who do not 108,109,111,112. Moreover, molecular 
profiling of CTCs for the detection of specific gene mutations or proteins that are relevant for 
the efficacy of certain cancer drugs, confers CTCs a substantial advantage compared to the 
methods routinely used for therapy response evaluation 207-210. 
To further validate the role of CTCs as indicators of treatment benefit, we have reported the 
usefulness of a panel of selected CTC-markers, detected by qPCR after CTC-enrichment, 
for the early identification of patients at high risk of treatment failure (chapter IV, page 93). 
The combination of CTC-related transcripts previously used for patient prognosis (GAPDH, 
VIL1 and CD45), with CTC-specific genes coming from our global CTC expression profile 
(CLU and TIMP1), together with LOLX3 and ZEB2 as EMT-related transcripts, due to the 
importance that this process potentially has in metastatic dissemination. Their analysis at 
various time points along treatment, allowed us to effectively discriminate between patients 
responding or not to a given therapy. Of note, from the global array of EMT transcription 
factors analyzed in this study (SNAIL1, SNAIL2, TWIST1, LOXL2, LOXL3, ZEB1, ZEB2 
and E47), only LOXL3 and ZEB2 were found to be CTC-specific. This highlights the need 
to assess non-classical EMT markers in CTC samples, for their better quantification and 
understanding, and again reinforces the importance of the EMT process in the field of CTC 
research. 
Importantly, using this method, we were able to assess treatment effectiveness, for most 
of the interrogated patients, only after 4 weeks, which represent a significant advantage 
compared to radiological imaging. Comparison of the results obtained using this methodology 
with the therapy response evaluation performed by computed tomography (CT) in this patient 
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cohort, showed that a significant percentage of patients (≈25%) might be being incorrectly 
classified by CT as responders, when indeed they are not. Those patients, identified as 
non-responders by CTC-markers, displayed a significant reduction in survival times when 
compared to patients classified as responders by both methods, strongly suggesting the 
evaluation of CTCs as an effective alternative for therapy response prediction. 
Even the insights shed by this methodology should be carefully interpreted due to limitations 
in sample size, its potential implementation in the routine clinical practice is currently under 
evaluation. In fact, these results have been patented (application number: 1438107.2), and 
PrediCTC, a kit for early therapy response evaluation in mCRC patients is under development. 
Ideally, after its validation in a large patient cohort, PrediCTC would be useful to select patients 
non-responding to therapy, candidates for a treatment change based on clinical standards. 
However, a parallel evolution in the field of cancer-drugs research is urgently needed to 
guarantee the existence of more effective alternative treatments to be applied to those 
patients identified as non-responders. 
Insights into cancer dissemination: lessons from CTCs
Evaluating patient prognosis and therapy response by means of the analysis of CTCs 
might provide beneficial information for the clinical management of patients with the final 
goal of personalized cancer treatment. However, the CTC-derived knowledge goes far 
beyond. The identification of CTC-specific molecules involved in some of the key processes 
enabling metastasis formation from CTCs, is critical for the better understanding of cancer 
dissemination, and at the same time holds the possibility of the discovery of CTC-based 
therapeutic targets.
To this regard, from the list of CTC-related genes described in chapter III, we have identified 
Talin1 as a molecule potentially implicated in the promotion of CTC extravasation from the 
circulation, which is a prerequisite for effective target organ colonization and subsequent 
metastasis formation (Chapter V, page 109). 
Talin1 is a protein that belongs to the integrin signaling pathway, and plays a key role in the 
connection of the cytoplasmic tails of β-integrins and the F-actin, thus providing a physical 
link between the extracellular matrix (recognized by integrins in the membrane) and the 
inner cellular cytoskeleton 234. Although the relationship of the integrin pathway with some 
of the steps of cancer invasion and metastasis has been widely investigated 218,310,336, little 
is known about the role of the Talin1 protein per se to this regard. Some previous reports 
have attributed a role for Talin1 in the process of cell death resistance under non-attachment 
conditions, also known as anoikis, or in the acquisition of an aggressive cellular phenotype 
leading to increased cancer cell invasion and metastasis formation 140,311.
Here, we found Talin1 as a CTC-specific marker, as its expression levels were significantly 
higher in CTC-enriched samples from mCRC patients compared with healthy controls. As 
the focus of the last part of this thesis, we investigated how Talin1 expression in CTCs could 
be involved in the process of CTC extravasation. We found that Talin1 depleted cells failed 
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to adhere to a monolayer of endothelial cells, the first barrier that CTCs find in their way out 
of the circulation. This could be, at least partially, because correct focal adhesion formation, 
and their interaction with fibronectin fibers superficially synthesized by endothelial cells, 
seemed to be, at least partially, relevant for this early cancer cell-endothelium interaction. 
Interestingly, we found that after Talin1 depletion, cancer cells also failed to both disrupt the 
endothelial layer and migrate through it to reach the underlying basement membrane, which 
also confers an obstacle to Talin1-depleted cells as proved in native basement membrane 
invasion assays. 
Altogether, these in vitro results can explain the marked metastasis formation ability of Talin1-
depleted cells when tested into a cancer dissemination animal model. This, in conjunction 
with the fact that Talin1 expression in CTCs showed both prognostic and predictive attributes, 
confer an interesting value to this molecule, both as a CTC-related biomarker, but also as a 
potential therapeutic target that could potentially deprive CTCs from their metastatic ability. 
A next step in this project is based on the high-throughput screening for active and specific 
anti-Talin1 compounds, which may finally translate this molecule into the clinics.
It is important to mention that the role of Talin1 seems to be cell or tumor type dependent. 
Very recently, it has been shown that in hepatocellular carcinoma (HCC), Talin1 may be 
repressing invasion and metastasis, and high Talin1 expression levels in primary HCC could 
confer good patient prognosis 337. Therefore, the need of future work is clearly evidenced to 
finally elucidate the role of this molecule in cancer progression. 
The results presented in this last part, together with the multimarker panel for therapy 
response prediction in mCRC, widely validate the strategy of developing an improved method 
for CTC detection and its molecular characterization as a source of CTC-related information. 
At the same time, highlights the importance of basic research in this field that opens a room 
for improvement of current tools available at the clinical setting.
In summary, the potential clinical value of CTCs is clear: early detection and treatment of 
metastatic disease are key for patient outcome and overall, there is increasing evidence 
that CTCs reflect cancer progression in real time, providing information that might cover the 
main fields related to cancer research: prevention, detection, treatment guidance and target 
discovery. However, there’s still a long way to go. Despite CellSearch® CTC counting has 
opened a promising way to the clinics, results obtained are still far from the global potential 
that CTCs might provide. Deeper understanding of CTC biology in terms of the elucidation 
of the differences between CTC subpopulation as well as the isolation and molecular 
characterization of potential tumor initiating cells, would open completely new avenues in 
the field of oncology. Although technically challenging, the application of the constantly 
improving single cell “omics”, or the optimization of CTC culture protocols for the real-time 
and patient-specific testing of drugs tackling metastasis, would ultimately determine the real 
clinical potential of CTCs.
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1. Anti-EpCAM magnetic immunoisolation of CTCs combined with their quantification 
by the assessment of VIL1, GAPDH and CD45 gene expression, generated an 
improved method for the analysis of circulating tumor burden in patients with 
metastatic colorectal cancer, in terms detection sensitivity and specificity. 
2. The logistic model built by combining VIL1, GAPDH and CD45 has shown a 
prognostic value, separating mCRC patients based on their clinical outcome, and 
identifying patients at high risk of disease progression.
3. We have developed an effective methodology for the evaluation of the global 
gene expression profile of samples containing very low amounts of starting 
genetic material. This technique, based on the combination of EpCAM-based CTC 
immunoisolation, whole transcriptome amplification and microarray hybridization, 
allowed the molecular characterization of CTCs from mCRC patients.
4. A specific set of 410 genes was found to characterize the population of CTCs 
isolated from mCRC patients. At the molecular level, this gene expression signature 
was related to a potential CTC phenotype mainly characterized by its adhesive and 
migratory abilities.
5. The specific expression of APP, CD9, CLU, ITGB5, LIMS1, RSU1, TIMP1, TLN1, 
VCL and BMP6 genes in CTC-enriched samples from mCRC patients, analyzed by 
qPCR, significantly validated our microarray analysis data. Moreover, the prognosis 
value of these CTC-markers, as well as their elevated expression levels in metastatic 
tissues compared to primary tumors, evidenced the usefulness of our methodology 
for the discovery of new and improved metastasis-related clinical biomarkers.
6. We have developed a panel of CTC-related markers, composed by GAPDH, VIL1, 
CLU, TIMP1, LOXL3, ZEB2 and CD45, for the evaluation of patient prognosis but 
more importantly, for the assessment of therapy response prediction in mCRC 
patients undergoing first-line treatment. 
7. We have shown that the sequential analysis of CTC-related transcripts along 
treatment constitutes an improved method for therapy response evaluation, when 
compared with standard computerized tomography. The implementation of this 
methodology at the clinical setting, in combination with routine imaging techniques, 
would improve current therapy effectiveness evaluation protocols. At this time, 
PrediCTC, a therapy response evaluation kit based on this methodology, is being 
designed and clinically validated on a multicenter trial. 
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8. We have demonstrated that the depletion of Talin1, a CTC-related molecule, in 
HCT116 and CT26 colorectal cancer cell lines, reduced their ability to attach and 
migrate through a monolayer of endothelial cells, key features in the process of 
CTC extravasation from blood.
9. We have identified a potentially new cancer cell-endothelium interaction mechanism, 
driven by the formation of focal adhesions by CT26 cancer cells at fibronectin-rich 
sites in the surface of endothelial cells. Talin1 represents a key component for the 
correct formation of these contact types. 
10. We have proved that Talin1 represents a crucial cellular component for the correct 
establishment and turnover of focal adhesions in HCT116 and CT26 cell lines and 
that, functionally, Talin1 regulates cell-ECM adhesiveness, migration and basement 
membrane invasion. 
11. We have shown up the role of Talin1 in cancer dissemination mediated by CTCs 
in an in vivo model, highlighting its biological importance in metastasis formation, 
reinforced by its increased expression, in human tissue samples, as tumor 
progression advances. Moreover, we have validated the gene expression analysis 
of Talin1 in CTC-enriched samples as a prognostic and predictive factor in mCRC 
patients. 
12. In closing, this thesis encompasses a global approach that, focusing on the study 
of circulating tumor cells in the process of cancer metastasis, aims to improve the 
current clinical tools available for a better patient management. As a whole, the 
establishment of new prognosis and predictive biomarkers, as well as potential 
therapeutic targets such as Talin1, widely evidence the clear translational 
commitment of this thesis. It represents an effort to transfer basic CTC-derived 
knowledge into a clinical application, with the ultimate intention of improving 
patient’s welfare.
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O Cancro Colorrectal
O cancro colorrectal (CCR) representa o terceiro tipo de cancro en canto a incidencia 
a nivel mundial, e o cuarto no referente a taxas de mortalidade, con aproximadamente 
690.000 mortes relacionadas con CCR no ano 2012, sendo lixeiramente máis habitual 
entre a poboación masculina 1, e cunha tendencia ao incremento especialmente en países 
en vías de desenvolvemento 3,4. A pesares disto, as taxas de mortalidade en países coma 
España rexistran unha redución paulatina dende o ano 2001 para ambos sexos 6, á que hai 
que sumar tamén un incremento progresivo das taxas de supervivencia dos pacientes con 
CCR 8,9, todo iso debido ás melloras en prevención, diagnóstico e tratamento deste tipo de 
tumores nos últimos anos. As taxas de supervivencia a 5 anos de pacientes afectados de 
CCR varían enormemente en función do estadio no que este sexa diagnosticado, cun 90,1% 
para CCR en estadios localizados, que se reduce a un 69,2% trala extensión tumoral cara 
a órganos adxacentes ou nódulos linfáticos, ou a un 11,7% xa nos casos máis avanzados 
nos que existe unha diseminación a órganos máis distantes 7. 
Aproximadamente un 5-10% dos casos de CCR son considerados de índole hereditaria, 
sendo o Cancro Colorrectal Hereditario Non Polipósico ou a Polipose Adenomatosa Familiar 
(HNPCC ou FAP, polas súas respectivas siglas en inglés), as dúas formas principais de 
CCR 10,11. A maioría dos casos de CCR teñen unha etioloxía esporádica, e factores como 
a idade, a presenza previa de pólipos no colon, ou certos factores ambientais teñen sido 
relacionados coa etioloxía deste tipo de cancro 10.
A nivel molecular, xa no ano 1990, Fearon e Vogelstein describiron un modelo de 
carcinoxénese colorrectal no que se propoñía a súa formación a partires da progresión 
paulatina de adenomas preexistentes 16, a través de mutacións secuenciais que resultan 
na alteración de polo menos 4-5 xenes (activación de oncoxenes e inactivación de xenes 
supresores de tumores). Aínda que se seguen a conservar as premisas formuladas neste 
modelo inicial, nas últimas dúas décadas describíronse outras rutas que contribúen ao 
proceso de carcinoxénese colorrectal. Estas inclúen a denominada inestabilidade de 
Microsatélites (ou MSI) 27,29, a ruta de metilación de illas CpG (CIMP) 31,32, a de inestabilidade 
cromosomal (CIN) 18, ou a máis recentemente descrita “Serrated pathway” (denominación 
inglesa pola morfoloxía en forma de dentes de serra das lesións nas que se observa) 34-36. En 
conxunto, todas estas características tumorais proporcionan información a nivel molecular 
que permite unha clasificación dos tumores dunha forma máis exacta, o que finalmente 
repercute nun mellor manexo e tratamento deste tipo de cancros. 
Se temos en conta a dramática redución das taxas de supervivencia nos estadios máis 
avanzados desta enfermidade, xunto coa lenta evolución da mesma (dende a presenza de 
adenomas ata o desenvolvemento de CCR) ponse claramente de manifesto a importancia da 
detección temperá neste tipo de tumores. Diversas metodoloxías que permiten a detección 
de sangue ou de determinadas proteínas asociadas ao CCR nas feces (FOBT e FIT) 57-59, 
ou de marcadores de CCR no soro sanguíneo (SEPT9, MMP7, PTGS2 ou CEA) 65-67, foron 
descritos como ferramentas útiles para a detección precoz de CCR. Neste senso, dende 
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o ano 2013, está implantado na comunidade galega un programa de detección precoz 
deste tipo de cancro, baseado no uso da técnica FOBT. Non obstante, o uso de técnicas 
de imaxe, que permiten a visualización e extirpación de lesións nun mesmo procedemento, 
constitúen o tipo de técnicas mais amplamente utilizado, polas consecuencias positivas 
que supoñen para o doente 57. Independentemente da técnica utilizada, a diagnose final 
do CCR faise en base ao resultado dunha colonoscopia, conxuntamente cunha biopsia do 
propio tumor e coa aplicación doutras técnicas de imaxe coma a tomografía de emisión de 
positróns (PET) para a detección de diseminación tumoral a distancia. Finalmente, a cada 
tumor asígnaselle un estadio en función dos resultados das probas anteriores, segundo a 
clasificación TNM que ten en conta tanto o tumor primario, coma a presenza de afectación 
nodular ou de metástases a distancia. 
A cirurxía constitúe o único tratamento curativo para este tipo de tumores, sempre e cando 
se encontren en estadios localizados 84. Aínda nestes casos, e para eliminar riscos de 
recorrencias pola presenza de células tumorais remanentes trala extirpación do tumor, 
é habitual a administración de terapias adxuvantes (complementarias á cirurxía) 85,338,339. 
Tamén, aínda que é máis frecuente no caso de cancro rectal, se poden aplicar terapias 
neo-adxuvantes  en determinadas situacións, para diminuír o tamaño do tumor antes da 
intervención cirúrxica 87. No caso da presenza de enfermidade metastática a distancia, 
a quimioterapia constitúe practicamente a única alternativa, e é aplicada normalmente 
cun fin paliativo, para mellorar a calidade de vida do paciente. A mesma, está baseada 
principalmente no uso de 5-fluoracilo normalmente en combinación con outros axentes 
(irinotecan ou oxaliplatino), e con terapias biolóxicas dirixidas (Bevacizumab ou 
Cetuximab) 10,11. 
A existencia de factores prognóstico (asociados coa evolución do doente en ausencia de 
terapia), ou predictivos (que permiten a identificación de pacientes con máis probabilidade 
de responder a unha terapia determinada), considérase hoxe en día fundamental para un 
mellor manexo dos pacientes con CCR. Un exemplo de factor prognóstico son os niveis 
do Antíxeno Carcinoembriónico (CEA) en soro, cuxos niveis elevados están asociados 
cunha peor evolución de enfermidade 72. Por outra banda, a presenza de mutacións 
activadoras do xene KRAS, constitúe un dos factores predictivos máis estudados en 
CCR, estando asociado coa resistencia a terapias anti-EGFR, ruta na que está implicada 
o propio KRAS 103. 
O proceso de metástase e as Células Tumorais Circulantes
Aínda que causante de máis do 90% da mortalidade relacionada co cancro 115,116, o proceso de 
metástase dista moito de ser completamente descifrado debido á súa elevada complexidade. 
O mecanismo polo cal as células epiteliais nos tumores primarios son capaces de xerar 
finalmente unha masa metastática a distancia, produce unha serie de eventos en serie, 
denominados en inglés “metastatic cascade 117”. Nun primeiro lugar, ditas células tumorais 
han de invadir a nivel local, para acabar atravesando a membrana basal, que separa o 
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compartimento tumoral do estroma veciño 118,119, para finalmente alcanzar os vasos, tanto 
sanguíneos como linfáticos, situados nas zonas adxacentes ao tumor primario, e entrar nos 
mesmos nun proceso denominado intravasación 115. Dito proceso de invasión caracterízase 
pola adquisición dun fenotipo máis mesenquimal por parte das células tumorais epiteliais, 
a través dun fenómeno denominado “Transición Epitelio-Mesénquima” ou EMT polas 
súas siglas en inglés. Grazas a isto, as células tumorais adquiren unha maior capacidade 
migratoria e invasiva, que lles permite avanzar cara a vasculatura e penetrar finalmente 
na mesma 134,161,294. Aínda que potencialmente ditas células tumorais teñen acceso tanto á 
circulación sanguínea como á linfática, no caso do CCR, tense descrito que a ruta principal 
de diseminación, e polo tanto de formación de metástases, é a hematóxena 115. 
Unha vez no compartimento circulatorio, estas Células Tumorais Circulantes ou CTCs 
teñen virtualmente acceso a tódolos órganos do corpo. Con todo, na maioría dos tumores 
obsérvase un claro patrón de metástase, con órganos diana preferenciais para cada tipo de 
tumor primario. No caso do CCR, o fígado constitúe o órgano principal en canto a formación 
de metástases, cos pulmóns en segundo lugar 141. A propia disposición anatómica pode 
explicar parcialmente este patrón, debido á existencia dunha circulación mesentérica que 
conecta directamente fígado e intestino 133. Emporiso, outros fenómenos como a liberación 
de factores solubles 148 ou microvesículas 147 por parte do tumor primario, poden colaborar na 
preparación do tecido diana antes da propia chegada das células tumorais que darán lugar 
á formación das metástases, xerando o que se denomina un “nicho premetastático” 145,146.
Unha vez na súa localización final, as CTCs han de abandonar a circulación para a posterior 
colonización no tecido diana, nun proceso denominado “extravasación”, no cal, estas se 
adhiren primeiramente ás células endoteliais que conforman a cara luminal dos vasos 
sanguíneos, e migran a través das mesmas (migración transendotelial ou TEM) 150,340. 
Finalmente, e tras alcanzar o estroma do tecido diana, unha subpoboación destas CTCs, 
as denominadas Células Iniciadoras de Tumores (ou TICs) 160 dará lugar á formación de 
micrometástases que serán as que finalmente orixinarán metástases macroscópicas 116.
A pesar do impacto que a aparición de metástases ten na supervivencia dos doentes 116, 
estudos en modelos animais suxiren que o proceso de formación das mesmas é altamente 
ineficiente, e calcúlase que unicamente un 0,02% do número total de CTCs liberadas 
á circulación a nivel do tumor primario darán lugar finalmente á formación de masas 
metastáticas macroscópicas 159. Aínda así, a formación das mesmas segue a representar a 
principal causa de mortalidade relacionada con cancro. 
O feito de que as CTCs representen un dos principais intermediarios no proceso de 
diseminación tumoral, con capacidade para, a lo menos a través dalgunha das súas 
subpoboacións, dar lugar á formación de metástases 172, fixo que nos últimos anos 
numerosos grupos de investigación se dedicasen ao seu estudo en profundidade. A propia 
bioloxía das mesmas, convérteas en candidatos moi atractivos para a análise do proceso de 
diseminación tumoral dunha forma dinámica e pouco invasiva, cos beneficios que iso pode 
reportar para a calidade de vida do doente. É importante ter en conta que, a día de hoxe, a 
maior parte das análises realizadas para determinar o prognóstico dun doente con cancro, 
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fanse a nivel do tumor primario 328. Non obstante, nun contexto de enfermidade metastática, 
a evolución do doente vén determinada pola presenza das propias metástases, tanto polo 
seu número e localización, como pola súa bioloxía intrínseca. Se, adicionalmente, temos en 
conta que o cancro constitúe unha enfermidade cun alto compoñente de variación temporal, 
a análise dunha única biopsia do tumor primario probablemente non estea reflectindo as 
características reais da enfermidade global do doente. Porén, a obtención de repetidas 
mostras de tecido (tanto do tumor primario como das propias metástases), representa un 
risco considerable para o doente. Se temos en conta que as CTCs poden provir tanto dos 
tumores primarios, coma das metástases a distancia xa formadas 117,169,170, xunto coa relativa 
accesibilidade ás mesmas a través da obtención de mostras de sangue, que poden ser 
repetidas ó longo do tempo, converte este tipo celular nun candidato realmente atractivo 
para a avaliación das características globais da enfermidade, na forma dunha “biopsia 
líquida”. 
Unha das limitacións máis importantes para a análise das CTCs vén dada pola súa escasa 
frecuencia de aparición, estimada nunha CTC por cada ≈107 células brancas por mililitro 
de sangue 173,174. Isto esixe o desenvolvemento de metodoloxías altamente específicas e 
sensibles para o illamento e cuantificación de CTCs. Nos últimos anos, un número elevado 
de tecnoloxías foron descritas con dita intención, baseadas no emprego de determinadas 
propiedades diferenciais entre as CTCs e o resto de células presentes de forma normal 
no sangue. A expresión de proteínas de membrana ou xenes específicos, así como o seu 
maior tamaño comparado coas células brancas, ou algunhas propiedades funcionais (por 
exemplo, invasividade), son algunhas das características mais empregadas para a captura, 
cuantificación e posterior caracterización molecular das CTCs (resumidas na táboa 9 da 
sección “introduction”). 
Na actualidade a única metodoloxía aprobada pola “Food and Drug Administration, FDA” 
americana, para a cuantificación de CTCs en cancros de mama, colorrectal e próstata 
metastáticos, é a plataforma CellSearch (Janssen Diagnostics, Raritan, NJ, USA). Esta 
basease no illamento de CTCs mediante o uso de partículas magnéticas acopladas a 
anticorpos anti-EpCAM (molécula de adhesión altamente expresada en células epiteliais), e 
na súa posterior detección por marcaxe positiva para as citoqueratinas 8, 18 e 19 (epiteliais), 
e negativa para CD45 (marcador de células brancas) 175-177. Aplicando esta metodoloxía en 
doentes con CCR metastático (CCRm), diversos grupos de investigación demostraron que 
a presenza de 3 ou máis CTCs (en 7,5mL de sangue) antes do inicio do tratamento, estaba 
claramente relacionada cun prognóstico desfavorable para o doente 76,77,177. Resultados 
similares en cancros de mama 175,199,201, próstata 200,202, ou pulmón 203, poñen de manifesto o 
valor prognóstico da cuantificación de CTCs neste tipo de doentes. 
De forma complementaria, a cuantificación de CTCs ao longo do tratamento mostrou 
ter un valor predictivo de resposta á terapia, pois reducións no número das mesmas 
despois da aplicación dun tratamento determinado, foron asociadas cun beneficio do 
doente en termos de supervivencia, tanto en mCRC 108,109,111,112, como en cancro de mama 
metastático 206. Ademais, a análise das CTCs permite a avaliación de xenes concretos, 
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cuxo estado mutacional pode ser relacionado coa maior probabilidade de responder a 
unha terapia dirixida. Neste sentido, a determinación de mutacións en KRAS ou BRAF 207 
en CTCs procedentes de doentes con mCRC, así como no EGFR en doentes con cancro 
de pulmón de células grandes (NSCLC, polas súas siglas en inglés) 208, preséntase como 
unha alternativa que, aínda pendente dun proceso de optimización metodolóxica, pode abrir 
novas vías no eido da predición de resposta a tratamento. 
As análises relacionadas coas CTCs non quedan exclusivamente restrinxidas á súa  contaxe 
ou á avaliación de mutacións puntuais en xenes de interese, senón que a determinación 
do seu perfil molecular estase a converter nun dos retos máis importantes a día de 
hoxe neste campo de estudo. Tanto a análise do perfil de expresión xénica destes tipos 
celulares 211,212, como a avaliación da presenza de alteracións xenéticas a nivel global 216, 
constitúen ferramentas que abren a posibilidade de atopar novos marcadores prognósticos 
e predictivos baseados en CTCs, ao mesmo tempo que proporcionan una información moi 
valiosa acerca da propia bioloxía de ditos dipos celulares. Iso abre unha nova vía para 
a mellor comprensión do proceso de metástase, e a identificación de potenciais dianas 
terapéuticas especificamente deseñadas para atacar de forma dirixida ao proceso de 
diseminación tumoral. No entanto, feitos como o reducido número de CTCs, ou os elevados 
niveis de contaminación por células sanguíneas presentes nas mostras, incluso despois do 
enriquecemento en CTCs, representan factores que limitan a obtención de información con 
este tipo de metodoloxías. Deste xeito, a mellora dos sistemas de illamento e cuantificación 
de CTCs, a implementación de novas metodoloxías que permitan o procesamento de 
volumes maiores de sangue para a obtención de maiores cantidades de material tumoral, 
ou o perfeccionamento das tecnoloxías de análise de célula única, son fundamentais para 
o avance deste campo de estudo que, aínda con moito camiño por percorrer, se considera 
prometedor. 
Deste xeito, e tendo en conta tanto as características do cancro colorrectal, do proceso de 
formación de metástases, e a importancia que o estudo das CTCs achega  para o mesmo, 
nesta tese formúlanse os seguintes obxectivos principais:
1. O desenvolvemento dunha metodoloxía mellorada para o illamento e cuantificación 
de CTCs en doentes con cancro colorrectal metastático.
2. A caracterización molecular de CTCs en doentes con cancro colorrectal metastático, 
en base ao seu perfil de expresión xénica.
3. A avaliación dun panel de marcadores de CTCs como unha ferramenta prognóstica 
e predictiva para a análise de resposta a terapia en doentes con cancro colorrectal 
metastático.
4. A caracterización do papel de Talina1 no proceso de diseminación metastática 
mediado por CTCs, e a análise de Talin1 como unha nova potencial diana terapéutica en 
cancro colorrectal metastático.
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Detección e cuantificación de CTCs
Na primeira parte desta tese descríbese a optimización dun método alternativo para 
o illamento e cuantificación de CTCs en doentes con CCRm, baseado no emprego de 
micropartículas magnéticas acopladas a anticorpos anti-EpCAM para a purificación de 
CTCs, combinado coa súa posterior detección mediante técnicas de PCR a tempo real. 
Ademais, o emprego dun método de extracción de RNA optimizado para mostras con 
escasa carga celular, xunto coa realización dun proceso de preamplificación previo á PCR, 
proporcionan niveis de sensibilidade adecuados para a efectiva detección de CTCs. 
A presenza de células illadas de forma inespecífica na mostra final (principalmente células 
brancas), fai que sexa necesario o uso dunha metodoloxía con elevada especificidade 
para a detección de CTCs. Finalmente, a combinación de VIL1 (xene expresado de forma 
específica no tecido intestinal), GAPDH (xene “housekeeping”, expresado de forma ubicua, 
e empregado como indicador da celularidade global presente na mostra), e CD45 (marcador 
específico de células de estirpe linfocitaria, empregado como avaliador dos niveis de 
illamento inespecífico), deron lugar a un modelo para a efectiva detección e cuantificación 
de CTCs en doentes con CCRm. Valores de área baixo a curva ROC próximos a 0,86 
evidencian as altas taxas de sensibilidade e especificidade alcanzadas por este método de 
detección, con valores superiores os doutras metodoloxías previamente descritas. Ademais, 
encontrouse unha relación significativa entre os niveis destes marcadores e a evolución 
clínica dos doentes, sendo peor naqueles con marcadores elevados, evidenciando o valor 
prognóstico desta metodoloxía. Aínda que a nivel de proba de concepto, estes resultados 
poñen de manifesto a utilidade deste sistema de detección para a súa incorporación en 
ensaios clínicos para a súa validación.
Avances na caracterízación molecular das CTC
Trala optimización dun método de illamento e detección de CTCs, xorde a necesidade de 
avanzar un paso máis cara a obtención dun perfil molecular completo deste tipo celular, o 
cal representa un dos aspectos máis atractivos, á par que desafiantes, da investigación no 
campo das CTCs 
Neste contexto, e baseándonos no método descrito anteriormente, na segunda parte desta 
tese levouse a cabo un estudo do perfil de expresión xénica xeral de CTCs illadas de 
doentes con CCRm. Trala amplificación lineal do seu transcriptoma completo, que permite 
a obtención de cantidades maiores de material xenético, levouse a cabo a hibridación en 
“arrays” de expresión xénica. Iso, combinado co emprego de mostras de doentes e controis 
sans, permitiu a identificación dun panel de 410 xenes específicos de CTCs neste tipo 
de doentes, principalmente implicados en funcións celulares como adhesión, migración, 
proliferación ou sinalización celular. Ditos resultados foron validados nun grupo de 20 
doentes e 10 controis sans, mediante qPCR para 11 xenes provenientes da lista inicial 
(410), obtendo diferenzas significativas entre ambos grupos para todos eles. É destacable 
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o feito de que, tras unha análise de supervivencia, tódolos xenes validados mostraron un 
valor prognóstico significativo, separando ós doentes en función da súa probabilidade de 
supervivencia, ademais dunha maior expresión (a diferentes niveis, dependendo do xene) 
en tecido metastático comparado co tumor primario.  
En conxunto, os resultados presentados nesta parte reforzan a importancia da identificación 
do perfil de expresión xénica das CTCs, como unha ferramenta para a identificación 
de posibles marcadores, tanto diagnósticos como prognósticos, ao mesmo tempo que 
proporciona información acerca da propia bioloxía de ditas CTCs, e polo tanto do proceso 
de metástase en si, moi relevante para o deseño de futuras terapias dirixidas. 
CTCs e predición de resposta a tratamento
A selección de terapias adecuadas para o tratamento do CCR metastático resulta crítica 
para un manexo efectivo deste tipo de doentes, cun impacto importante na supervivencia 
dos mesmos. Actualmente, a avaliación de resposta a tratamento efectúase principalmente 
mediante técnicas de imaxe, en base ao resultado das cales se decide o mantemento ou 
cambio dunha terapia determinada. Porén, este tipo de metodoloxías non proporcionan 
información tan rápido nin efectivamente como moitas veces é necesario na práctica clínica 
diaria. Deste xeito, moitos doentes poden estar sendo tratados durante longos períodos 
de tempo cunha terapia inefectiva, coas respectivas consecuencias para os mesmos, 
normalmente relacionadas coa propia toxicidade dos tratamentos. 
Nesta tese propoñemos a utilización dun panel de marcadores de detección de CTCs 
en doentes con CCRm, para a avaliación de resposta a tratamento dunha forma eficaz e 
temperá. A análise de CTCs con este fin presenta certas vantaxes fronte ás metodoloxías 
convencionais, xa que poden ser analizadas de forma repetida ao longo  do tempo de 
tratamento, dunha forma minimamente invasiva e inocua para o doente, á vez que poden 
proporcionar información dunha forma máis rápida e menos custosa que as técnicas de 
imaxe. 
A combinación de marcadores específicos para a detección CTC, obtidos nos traballos 
correspondentes ás primeiras partes desta tese (GAPDH, VIL1, CLU e TIMP1), xunto con 
outros relacionados co proceso de EMT (ZEB2 e LOXL3), todos eles normalizados pola 
expresión de CD45, xerou un panel de marcadores efectivo tanto para a avaliación do 
prognóstico dos doentes, como para a predición de resposta a tratamento nos mesmos. A 
avaliación dos niveis de expresión de ditos xenes levouse a cabo en 50 doentes con CCRm 
antes e despois do inicio do tratamento. Empregando esta metodoloxía, fomos capaces de 
avaliar a resposta a tratamento na maioría dos doentes tras tan só catro semanas despois 
do inicio do mesmo, moito antes que as técnicas de imaxe convencionais (normalmente 
tres meses). Aqueles doentes que presentaron unha redución dos niveis de marcadores de 
CTCs, mostraron unha maior supervivencia, comparados nos que se encontrou un aumento 
dos mesmos. É de destacar a existencia dunha porcentaxe de doentes (≈25%) clasificados 
como respondedores por técnicas de imaxe, e que esta metodoloxía identificou como non 
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respondedores. Estes doentes presentan un tempo de supervivencia significativamente 
máis curto que aqueles clasificados como respondedores por ambos métodos, o que pon de 
manifesto a clara superioridade do emprego destes marcadores de CTCs para a avaliación 
temperá da resposta a terapia. 
Os resultados desta parte da tese deron lugar á solicitude dunha patente europea, e 
actualmente estase a desenvolver un kit de predición de resposta a terapia, que será 
avaliado nun número máis amplo de doentes con CCRm nun ensaio clínico multicéntrico. 
Todo iso, co fin de poder implantar esta metodoloxía na práctica clínica diaria, co evidente 
beneficio que pode supoñer para a calidade de vida dos doentes. 
CTCs e a bioloxía do proceso de metástase
A información que as CTCs poden chegar a proporcionar vai mais alá do seu valor 
prognóstico ou predictivo. Como xa se comentou, a identificación de moléculas CTC-
específicas, involucradas en procesos chave na diseminación tumoral, resulta crítica 
para unha mellor comprensión da mesma, e ao mesmo tempo abre unha nova vía para o 
establecemento de novas dianas terapéuticas máis efectivas, dirixidas de forma específica 
contra o proceso de metástase mediado por CTCs. 
Neste sentido, na derradeira parte desta tese identificouse Talina1, molécula pertencente 
á ruta das integrinas e involucrada na adhesión das células á matriz extracelular que 
as rodea, como un marcador específico de CTCs en doentes con CCRm. O bloqueo in 
vitro da expresión de Talina1 en liñas celulares de CCRm deu lugar a unha redución no 
número de adhesións focais, así como á diminución das capacidades tanto adhesivas 
como migratorias destes tipos celulares. Ademais, encontramos que Talina1 xoga un papel 
fundamental no proceso de adhesión das células tumorais ás células endoteliais, primeira 
barreira que encontra unha CTC durante o proceso de extravasación, no seu camiño cara 
a colonización dos tecidos diana para a posterior formación de metástases. Describimos 
tamén que dita adhesión se leva a cabo, a lo menos en parte, grazas á interacción que se 
establece entre as adhesións focais das células tumorais e fibras de fibronectina que as 
células endoteliais producen na súa superficie. A maiores, despois do bloqueo da expresión 
de Talina1, as células tumorais mostraron unha habilidade diminuída para migrar a través 
dunha monocapa de células endoteliais e da membrana basal situada inmediatamente 
debaixo das mesmas. Todos estes resultados in vitro  explican a escasa capacidade das 
células para, en ausencia de Talina1, dar lugar á formación de metástases trala inxección 
das mesmas nun modelo animal. Se a iso lle sumamos a capacidade tanto prognóstica 
como predictiva que presentaron os niveis de expresión de Talina1 en CTCs de doentes 
con CCRm, queda claramente reflectida a importancia clínica desta molécula a tódolos 
niveis. 
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En resumo, o traballo recollido nesta tese engloba o establecemento dunha nova 
metodoloxía para o illamento e cuantificación de CTCs provenientes de doentes con CCRm, 
dunha forma sensible e específica, que posibilitou a posterior avaliación do seu perfil de 
expresión xénica, clave para o mellor entendemento da súa propia bioloxía. Ademais, e 
partindo da información obtida nos dous primeiros traballos, levouse a cabo o deseño dun 
panel de marcadores para a detección de resposta a terapia dunha forma sinxela, rápida 
e efectiva. Por último, a validación de Talina1 como unha molécula relevante durante 
o proceso de extravasación das CTCs da circulación e o posterior establecemento de 
metástases, e polo tanto como unha potencial diana terapéutica para o control do mesmo, 
pon de manifesto o valor global do estudo das CTCs en tódalas facetas relacionadas co 
manexo clínico dos doentes con CCRm.
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